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ABSTRACT 
 
Helicobacter pylori is a microaerophilic, gram-negative bacterium and among the 
most persistent of all human pathogens.  Its presence in the gastric environment is corre-
lated with diseases such as gastritis, peptic ulcers, mucosa-associated lymphoid tissue 
lymphoma, and gastric carcinoma.  Multiple factors are believed responsible for disease 
progression and outcome including infecting strain(s) genetic composition, age of acqui-
sition, host immune response, environment, and diet.  Due to the complexity of H. pylori 
infection, all possible host-pathogen interactions should be considered.  One important 
factor frequently underplayed is host dietary habits which may serve a more important 
role during and immediately following infection with H. pylori than previously thought. 
It has been shown that people consuming diets rich in fruits and vegetables have a 
lower incidence of H. pylori infection and severe gastric malignancies and that this may 
be in part due to natural bioactive compounds acting against H. pylori.  We believe that 
alternative, diet-based strategies may have a significant impact on attenuating this bacte-
rium when used alone or in combination with current antibiotic regimes; however, natural 
compounds should be better studied to understand their full therapeutic potential.   
Muscadine grapes, because of their high levels of polyphenolic compounds and 
unique chemical makeup, are believed to be a proper candidate for study since these 
fruits have already been shown to exert anti-H. pylori activity in vitro with effects possi-
bly related to inhibition of bacterial attachment and virulence factors.  The objectives of 
this study were to 1) identify active phenolic compounds in muscadine grape skin respon-
sible for anti-H. pylori activity, 2) use DNA microarrays to study gene expression upon 
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exposure to active compounds, and 3) explore the preventative potential of muscadine 
grape skin and identified polyphenols for ameliorating H. pylori infection and/or the H. 
pylori-induced inflammatory response in mice. 
 Our results show that muscadine grape skin and major phenolics quercetin and 
resveratrol exert strong anti-H. pylori activity; especially when in combination, and may 
have the potential to be incorporated into an effective, diet-based approach for the pre-
vention and/or treatment of H. pylori infection. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
Introduction 
Helicobacter pylori is a gram-negative, spiral-shaped, microaerophilic bacterium 
and a resident of the human gastric environment.  Since its discovery in 1983, countless 
studies have sought to better understand this microorganism and its role in human patho-
genesis.  In 1994, H. pylori was classified as a carcinogen by the World Health Organiza-
tion (WHO) (International Agency for Research on Cancer meeting) and is currently rec-
ognized as the etiologic agent of peptic ulcers and gastritis and strongly linked to muco-
sa-associated lymphoid tissue (MALT) lymphoma and gastric carcinoma (Cover and 
Blaser, 1995).  This pathogen infects more than half the world‘s population making it one 
of the most common bacterial infections in humans (Rothenbacher and Brenner, 2003).  
However, the majority of those infected develop asymptomatic gastritis while approx-
imately 10-20% develop more severe diseases like peptic ulcers, atrophic gastritis, 
MALT or gastric carcinoma (0.1-4%) (Bourzac and Cuillemin, 2005).  Because infection 
with H. pylori does not necessarily correlate with clinical symptoms, multiple factors are 
believed responsible for disease progression and outcome including infecting strain(s) 
genetic composition, age of acquisition, host immune response, environment, and diet 
(Blaser and Atherton, 2004). 
Due to the complexity of H. pylori infection, all possible host-pathogen interac-
tions should be considered.  One important factor frequently underplayed is host dietary 
habits which may serve a more important role during and immediately following infec-
2 
 
tion with H. pylori than previously thought (Testerman et al., 2001).  Once H. pylori co-
lonizes the gastric epithelium, although relatively safe from acidic conditions; protected 
by the thick gastric mucosa, it is still exposed and vulnerable to various solutes.  There-
fore, it is possible that host dietary compounds may play a beneficial role in H. pylori 
prophylaxis and/or treatment.  Some studies have previously explored the link between 
H. pylori infection and host diet/nutrition with several associating high-salt diets with an 
increased risk and/or extent of disease (Tsugane et al., 1994; Fox et al., 1999; Willis et 
al., 1999; Gancz et al., 2008).  On the other hand, consumption of fruits and vegetables 
rich in certain vitamins, antioxidants, and constitutive bioactive compounds (i.e. phyto-
chemicals) has been shown to significantly reduce the incidence of H. pylori infection 
and/or ameliorate associated symptoms (Buiatti et al., 1990; Zhang et al., 1997, Benned-
sen et al., 1999, Yamada et al., 1998; Fukai et al,. 2002, Yanaka et al., 2009).   
Although many strains of H. pylori are susceptible to most currently used antibio-
tics (e.g. clarithromycin, metronidazole, amoxicillin) in vitro, treatment is increasingly 
challenging due to antibiotic resistance and reinfection in certain groups.   Because the 
effective lifespan of any antibiotic is limited, the search for new antimicrobials has risen 
dramatically in recent years.  In addition, increased public awareness of the over-
use/misuse of prescription antibiotics coupled with the desire for greater autonomy over 
personal medical care has led to increased demand for natural, safe alternative medica-
tions.  Therefore, novel, diet-based therapeutics for use where conventional antibiotic 
therapies have failed, are unavailable or rejected, and/or expensive have received consi-
derable attention.   
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Numerous studies have investigated novel, naturally occurring, plant-derived sub-
stances as potential alternatives for H. pylori prevention or treatment (O‘Gara et al., 
2000; Bergonzelli et al., 2003; Lin et al., 2005; Paraschos et al., 2007; Yang et al., 2008; 
De et al., 2009; Martini et al., 2009; Pastene et al., 2010).  In particular, studies have 
shown that grapes (Vitis vinifera) and their extractable bioactive compounds, especially 
polyphenols, have strong anti-H. pylori activity; inhibiting growth (Mahady and Penland, 
2000; Mahady et al., 2003) in a variety of strains while reducing H. pylori-induced in-
flammation and gastritis in infected animal models (Tombola et al., 2003; Yahiro et al., 
2005; Ruggiero et al., 2006; Ruggiero et al., 2007).  We have previously reported that 
muscadine grapes (Vitis rotundifolia) are also a valuable source of anti-H. pylori com-
pounds with activity against multiple strains in vitro.  In addition, we believe that musca-
dine‘s reported biological activity is most likely due to major phenolic compounds (i.e. 
ellagic acid, myricetin, quercetin, trans-resveratrol, gallic acid) present in these fruits act-
ing alone or in synergy (Brown et al., 2009).  Although these polyphenols are ubiquitous 
in nature, the combination of ellagic acid, quercetin, and resveratrol is unique to musca-
dine species and may further suggest that these compounds are largely responsible for 
their reported biological activities (Mertens-Talcott and Percival, 2005) and be useful in 
the treatment of H. pylori infection. 
Background and Significance 
Before Helicobacter pylori‘s discovery (Marshall and Warren, 1984), the human 
stomach was considered to be sterile, or at most transiently populated by oropharyngeal 
bacteria (Blaser 1997).   Today, H. pylori is considered a ubiquitous gastric pathogen and 
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firmly established as the causative agent of acute or chronic gastritis as well as a predis-
posing factor in peptic ulcer disease, gastric carcinoma, and B-cell MALT (Mitchell, 
2001).  In 1994, H. pylori was the first bacterium classified as a class I carcinogen by the 
WHO following epidemiological studies prompted by its association with severe gastric 
malignancies (e.g. MALT and stomach cancer).   
H. pylori infects more than half the world‘s population making it one of the most 
common bacterial infections in humans (Rothenbacher and Brenner, 2003).  Although 
infections occur worldwide, significant differences in the prevalence of infection exist 
with highest rates in developing countries—primarily attributed to the rate of acquisition 
in childhood (Mitchell et al., 1992).  However, additional factors likely contribute to in-
fection including low socioeconomic status, diets low in raw vegetables, fruits, and high 
fiber breads, unclean water supplies, overcrowding, etc.  In addition, factors such as host 
genetics, immune response, etc. are also believed to play a critical role.  It is generally 
agreed that, once infected, without treatment most persons remain infected for life 
(Pounder and Ng, 1995).  Although infection is usually asymptomatic, with symptoms 
observed in only 15-20% of those infected; the organism is believed to be highly trans-
missible (presumably via the fecal-oral route) and damaging to the host, causing progres-
sive destruction to the gastric mucosa over the lifetime of infection (Parosonnet, 1999). 
Epidemiological studies have reported an overall decline in H. pylori transmission 
worldwide, most likely due to improved sanitation in recent decades.  This trend suggests 
that H. pylori will eventually be eliminated from the U. S. population.  However, without 
proper intervention, it is predicted that endemic H. pylori infection will remain in the 
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U.S. for at least another century and even longer in developing countries necessitating 
effective treatment (Rupnow et al., 2000; Suerbaum and Michetti, 2002). 
Helicobacter pylori 
 Helicobacter pylori is a gram-negative, spiral-shaped microaerophile and typical-
ly measures 2.5 to 5 µm long and 0.5 to 1 µm wide.  Although most often observed in its 
spiral form, H. pylori is also capable of a spherical morphology resembling a coccoid and 
may be a stress response mechanism for minimizing contact with unfavorable environ-
mental conditions (Hessey et al., 1990).  H. pylori found in the environment are believed 
to exhibit this type of morphology; constricting themselves, decreasing their surface area, 
and entering into a viable-but-nonculturable physiological state.  In this state, the organ-
ism can still infect but cannot be detected by culturing methods.  
H. pylori is fastidious and microaerophilic, thus requiring an enriched medium 
and atmosphere with reduced oxygen (approximately 10% CO2) and an optimum growth 
temperature of 37C.  The pH ranges from 5.5 to 8.5 with an optimal pH between 6.9 and 
8.  Growth is slow, typically requiring 3-5 days for colonies to be observed.  When colo-
nies are visible, they are approximately 1 mm in diameter and appear smooth and translu-
cent; however, this characteristic may be strain dependent.  H. pylori biochemical charac-
teristics include positive tests for oxidase, catalase, urease, and acid and alkaline phos-
phatases (Rathbone and Heatley, 1992; Northfield and Mendall, 1994). 
Pathogenicity 
Although the gastric mucosa is inherently well protected against most microbial 
attacks, H. pylori has successfully adapted to this extreme environmental niche.  For H. 
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pylori to cause infection and subsequent disease in a host, various components are re-
quired for initial adherence, colonization, and cellular damage.  This review will briefly 
discuss the most important factors necessary for H. pylori‘s survival and virulence in the 
human stomach.  
Motility 
In order to establish a successful infection, H. pylori must first evade the highly 
acidic gastric secretions (pH 1.2-3.0) of the stomach, relying heavily on its ability to 
move quickly through the gastric mucosa.  To do this, H. pylori uses its powerful flagella 
and spiral shape to corkscrew through the thick, viscous mucous layers to reach the un-
derlying epithelial tissue.  The flagella, typically four to five, are located at one pole of 
the cell and sheathed—believed to be an adaptation to the acidic conditions for moving 
through the mucosa thereby protecting the filaments from depolarization.  Each flagellar 
filament contains two flagellin proteins, FlaA and FlaB encoded by the flaA and flaB 
genes (Kostrzynska et al., 1991).  If one gene is removed, the organism exhibits de-
creased motility and if both are absent, the cell is immobile and unable to colonize (Jo-
senhans et al., 1995; Ottemann and Lowenthal, 2002). 
Urease 
H. pylori urease is essential for colonization of the stomach as it allows survival 
under acidic conditions—accounting for up to 15% of the total protein synthesized by the 
organism (Prinz et al., 2003; Mobley et al., 1995).   Urease is a Ni
2+
-containing cytop-
lasmic enzyme that converts urea into bicarbonate and ammonia.  These products gener-
ate a protective alkaline microenvironment and allow the organism to persist in this acid-
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ic milieu (Mobley, 2001).  Urease activity is regulated by pH-gated urea channels (UreI) 
in the inner membrane, unique to H. pylori, which open at low pH (< 6.5) and close under 
neutral conditions, regulating the influx of urea into the cell.  Ammonia produced diffus-
es into, and thus buffers the periplasm (Prinz et al., 2003; Weeks et al., 2000; Weeks et 
al., 2001).  The role of this enzyme in H. pylori’s pathogenesis became evident after find-
ing that strains with decreased urease activity were unable to initially colonize stomach 
epithelium resulting in no infection even while possessing all other virulence components 
(Eaton et al., 1991).   
Adherence 
Following initial colonization, H. pylori must securely attach to the stomach epi-
thelial tissue to resist removal by peristalsis and gastric epithelial cell turnover.  H. pylori 
is able to adhere, in part through binding to blood group antigens, expressed on gastric 
epithelial cell surfaces, with the most important being the Lewis
 
b antigen (Atherton, 
2006; Borén et al., 1993; Marshall, 1994).  Other proteins including those found in the 
outer-membrane protein (Hop) family may also influence adhesion to epithelial cells and 
are briefly discussed below. 
Adhesins.  H. pylori binds to a variety of carbohydrate ligands on host epithelial 
cells, including sialic acid (Lelwala-Guruge et al., 1993), laminin (Valkonen et al., 1997), 
gastric mucin (Namavar et al., 1998) and fucosylated glycoproteins such as the Lewis
 
b 
(Le
b
) antigen (Borén et al., 1993; Guruge et al., 1998).  Strains expressing the binding 
adhesin BabA, a 78-kD outer-membrane protein, encoded by the babA2 gene, have the 
ability to bind to difucosylated Le
b
 blood group antigens expressed on gastric epithelial 
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cells, functioning as receptor molecules (Gerhard et al., 1999; Monteiro et al., 1998).  
Lewis
 
b is expressed on H. pylori cell surfaces with expression mimicking human cell 
surface glycolipids, causing a decreased anti-H. pylori T-cell response by the host (Sher-
burne and Taylor, 1995).  This in turn generates increased host epithelial cell prolifera-
tion and inflammation while increasing the risk for gastric ulcer and cancer development 
(Atherton, 2006).  However, even with Lewis
 
b binding adhesins, some H. pylori strains 
may not bind to epithelial cells with Le
b
 antigens.  If this happens, the organism is able to 
utilize many of its other adhesins from Hop for cell attachment.  Lewis a and Lewis x, 
mediated by SabA (sialic-acid-binding adhesin), are two other blood group antigens ex-
pressed on epithelial cells; however, these are not as important as Le
b
.  It was shown by 
Sheu et al. (2005) that mice expressing Le
b
 developed gastritis while wild-type mice 
without Le
b
 expression did not; supporting the importance of this ligand-receptor interac-
tion for disease. 
Another putative adhesin, part of the outer membrane, is the HopZ protein which 
mediates binding to gastric epithelial cells but does not function as a porin (Peck et al., 
1999).  Outer membrane proteins HopB and HopC may also function in a similar fashion 
but have yet to be extensively studied (Exner et al, 1995).  In addition, cell-envelope pro-
teins other than suspected porins have also been implicated as adhesins including Hpa, 
identified as a flagellar sheath lipoprotein.  Despite extensive research on H. pylori in vi-
tro, there is little agreement on which H. pylori adhesins are most important in vivo due 
to a multitude of possible host-pathogen interactions (Testerman et al., 2001). 
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Cellular Damage 
After colonizing the gastric epithelium, H. pylori causes damage to epithelial 
cells; in turn promoting continual regeneration of the gastric epithelial layer.  Damage is 
a result of multiple factors including bacterial toxin production, secretion of phospholi-
pase and protease enzymes, inflammation, and promotion of a self-destructive host im-
mune response.  
Cytotoxin-associated genes.  Of those infected with H. pylori, relatively few de-
velop clinical symptoms.  This phenomenon may be largely attributed to strain-specific 
differences with one of the most important being cagA status.  H. pylori strains bearing a 
complete cag pathogenicity island (PAI), a 37-kb genome segment encoding about 30 
genes, including cagA, are often associated with increased gastric inflammation and bac-
terial colonization, peptic ulcer disease, gastric cancer and higher induction of gastric epi-
thelial cell cytokines responsible for recruiting/activating immune inflammatory cells 
(Peek et al., 1995; Blaser et al., 1995; Crabtree et al., 1995; Sharma et al., 1995, Figuei-
redo et al., 2005).  These genes are used to encode products similar in composition to that 
of type IV secretion systems—allowing H. pylori to deliver the CagA effector protein 
into host cells—activating specific transcription factors and cell signaling pathways 
(Ding et al., 2007, Li et al., 1999; Keates et al., 1997). 
CagA.  CagA is a 128-kDa protein that elicits a strong immunological response 
and is used as a marker for the presence of a large pathogenicity island (PAI) encoding 
many proteins with several implicated in H. pylori pathogenesis (Censini et al., 1996; 
Prinz et al., 2003).   
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After entering the cell, multiple changes in host cell signaling are made, usually 
when the protein is phosphorylated and binds to SHP-2 tyrosine phosphatase (Higashi et 
al.,2002) triggering a growth factor-like cellular response and cytokine production by the 
host cell (Suerbaum and Michetti, 2002).  This may support the organism‘s link to gastric 
cancer because of the activation of SHP-2, a protooncogene.  CagA-positive strains have 
also been found to increase virulence and cell injury with studies showing cagA-positive 
infected patients with higher incidences of peptic ulcers and gastric cancer development 
(Gold, 1994; Blaser et al., 1995; Peek et al., 1997).  In a related in vitro study, Smoot et 
al. (1999) supported the finding that cagA-positive strains were associated with greater 
cell injury than cagA-negative strains; however, less apoptosis of cell tissue was observed 
following exposure to cagA-positive strains than cagA-negative strains (Peek et al., 
1997).  These findings suggest that cagA-positive strains generate more cell damage but 
less apoptosis than those infected with cagA-negative strains.  Because of this, gastric 
epithelial cells exposed to cagA-positive H. pylori may be allowed to continue their cellu-
lar cycle with an increased chance of replication with DNA damage (Smoot et al., 1999).  
This was later supported by Obst et al. (2000) who observed that gastric cells exposed to 
cagA-positive H. pylori extract did not show any change in the percentage of cells in the 
G2M phase of the cellular cycle but had increased levels of reactive oxygen species 
(ROS), DNA fragmentation and DNA synthesis. 
Vacuolating cytotoxin.  All H. pylori strains, regardless of cagA status, contain a 
copy of the vacA toxin gene.  VacA toxin is an important virulence factor directly in-
volved in gastric inflammation and ulceration (Ghiara et al., 1995; Eaton et al., 1997).  Of 
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the various vacA allele types identified, the most important and extensively studied is 
s1/m1.  Strains possessing this allele typically encode VacA proteins associated with a 
higher level of vacuolating cytotoxin activity compared to other allele types.  In addition, 
cagA-positive strains are more likely to produce this exotoxin (Montecucco et al., 2001).  
VacA is composed of identical 87-kDa monomers assembled into flower-shaped oligo-
mers.  This toxin manipulates intracellular vesicular trafficking in host epithelial cells, 
generating cytoplasmic vacuoles (Reyrat et al., 2000), membrane channel formation, dis-
ruption of endosomal/lysosomal function, immunomodulation, and apoptosis (Figueiredo 
et al., 2005).  Additional hypotheses for its activity have been proposed including forma-
tion of anion-selective membrane channels and interaction with a receptor-like protein 
tyrosine phosphatase (RPTPß); however, the primary mechanism is currently unknown.  
After reaching the endosome via internalization through a vacuole, it is not known what 
happens to VacA.  However, it is proposed that once in the endosome, the toxin may in-
hibit energy activation and cause mitochondrial damage, leading to cell cycle impairment 
and cell death. 
Most people in Western countries with severe gastritis are infected with VacA H. 
pylori variant strains; however, this association has not been found in Asia and has yet to 
be fully explained (Atherton et al., 1997).  Strains with inactive vacA genes have been 
isolated from countless patients, indicating that VacA is not essential for colonization.  
However VacA-negative mutants were shown to be out competed by wild-type bacteria 
in one animal study, possibly suggesting that VacA-positive bacteria might be hardier 
and more competitive in vivo (Salama et al., 2001).  Currently, it is still unknown whether 
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VacA causes epithelial cell death in humans.  However, strong evidence using mice does 
exist showing oral administration of VacA does lead to gastric epithelium erosion, pre-
sumably involving cellular loss. 
Immune Response 
A remarkable feature of H. pylori is its ability to persist throughout the life of the 
host despite significant immune responses aimed to destroy it.  Once ingested, H. pylori 
must quickly move through the gastric mucosa to gain access to the underlying epithe-
lium.  While in the mucosa, nonspecific, antimicrobial molecules such as lactoferrin, ly-
sozyme, and defensins are encountered; however H. pylori expresses mucolytic mole-
cules (e.g. protease, lipase) which aid in evasion of these factors (Nakao et al,. 1997; 
O‘Neil et al., 2000).  In addition, gastric acid is also present; however, H. pylori urease 
effectively buffers its environment until it gains access to its target tissue (discussed ear-
lier).  Once situated adjacent to gastric epithelial cells, H. pylori adheres and begins colo-
nization.  Unfortunately, the gastric microenvironment is relatively absent of immune and 
inflammatory cells in uninfected, normal gastric mucosa (attributed to the fact that few 
microorganisms can handle gastric acid); therefore, this may provide the time required 
for H. pylori to expand and establish persistent infection.  Having evaded innate res-
ponses, H. pylori then encounters adaptive responses mediated by B and T lymphocytes.  
T-cell responses will be discussed further. 
Following colonization of the gastric epithelium by H. pylori, the induction of an 
inflammatory response, predominantly of the Th1 type occurs (Kuipers et al., 1995).  
This response is triggered by Th1 cells stimulating epithelial cells to produce proinflam-
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matory cytokines [(e.g. tumor necrosis factor (TNF)-α, interleukin (IL)-1-β, interferon 
(IFN)-γ, and IL-8)] that recruit and activate host phagocytes (e.g. neutrophils and macro-
phages).  In addition, release of reactive oxygen radicals (e.g. hydrogen peroxide, hy-
droxyl radicals, superoxide anions) during phagocytosis is also believed to contribute to 
the inflammatory process.  In turn, this influx of proinflammatory cells is responsible for 
much of the destruction associated with acute phase gastritis and can impart an oxidative 
stress that causes damage to epithelial cells as well as to cellular DNA.  Therefore, the 
Th1 response results in epithelial cell damage rather than removal of H. pylori.  The on-
going presence of H. pylori thus causes a lifelong proinflammatory response coupled 
with host-responsible cellular damage.  Finally, gastric T cells can also modulate B-cell 
responses, possibly leading to the production of antibodies (IgG) that can activate the 
complement cascade and contribute to immune-complex mediated inflammation (Wang 
et al., 2001). 
The continuous source of oxidative stress and corresponding inflammation result-
ing from this long-term infection can give rise to DNA damage, thereby inducing the 
multiple mutations believed necessary for initiation of the ―cancer cascade‖ (Correa et al., 
1975; Kusters et al., 2006). 
Interestingly, there is a marked difference in the ability of H. pylori to induce epi-
thelial cytokines.  Epithelial IL-8 (Crabtree et al., 1994) and associated NF-κB activation 
(Sharma et al., 1998) is only induced by strains carrying the cag PAI further supporting 
its role in the immune response and H. pylori pathogenesis.  Following initial acute ga-
stritis, active chronic gastritis occurs which can last a lifetime if infection remains un-
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treated.  However, the majority of H. pylori-positive subjects are unaware of this due to 
the lack of clinical symptoms.   
Conventional Treatment of H. pylori Infection 
  Currently, no vaccine for H. pylori infection exists.  However, treatment is still 
relatively successful (> 80%) using a combination of antibiotics, i.e. ‗triple therapy‘ con-
sisting of two antibiotics plus either a proton-pump inhibitor (PPI, e.g. pantoprazole, 
omeprazole, rabeprazole) or bismuth compound (e.g. bismuth subsalicylate).  Treatment 
time is usually one to two weeks with one of the following combinations: a PPI plus cla-
rithromycin and amoxicillin, (2) a PPI plus clarithromycin and metronidazole, or (3) bis-
muth subsalicylate plus metronidazole and tetracycline (Howden and Hunt, 1998; Gaby, 
2001). 
Although treatment with multiple antibiotics increases eradication rates and re-
duces resistant H. pylori strain selection, various problems still arise through their use 
and has led to the still ongoing search for the most appropriate therapy (Mégraud et al., 
2001; Suerbaum and Michetti, 2002).  Depending on the patient and selected treatment, 
side effects such as diarrhea, nausea, vomiting, bloating, and abdominal pain frequently 
occur (Canducci et al., 2000).  In addition, failure to complete prescribed treatments, 
most often because of these side effects, may further explain why treatments often fall 
short of effectively eliminating this pathogen and result in higher rates of reinfection fol-
lowing treatment (Del Giudice et al., 2001). 
Eradication therapies are required to have cure rates of at least 80 percent with no 
significant side effects, and induce minimal bacterial resistance (Suerbaum and Michetti, 
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2002).  With these strict guidelines, monotherapies are currently unable to achieve this 
result.  Thus, drugs in combination as described above are recommended and most often 
employed.  However, even with these treatment regimens, eradication rates still vary.  
This may be because of poor patient compliance, inappropriate evaluation by a health 
provider, and primary or secondary antibiotic resistance (Canducci et al., 2000).  In addi-
tion, antibiotics themselves may not be able to penetrate the thick gastric mucosa enough 
to be effective or may be inactivated by the stomach acids before reaching its target (Ka-
wase and Motohashi, 2004) and are dependent on the prescribed drug combination and 
degree of infection (Michetti et al., 1999). 
Even with proper antibiotic therapy, the potential for antibiotic resistance devel-
opment against commonly prescribed drugs like metronidazole, tetracycline, amoxicillin, 
and clarithromycin is on the rise (Graham, 1998; Yang et al., 2001).  Resistance to amox-
icillin and tetracycline is still relatively low for H. pylori.  However, clarithromycin and 
metronidazole resistance is currently around 10 and 30 percent, respectively in the U.S. 
and even higher in some developing countries (Meyer et al., 2002).  Such high levels of 
resistance may be partly attributed to the extensive use of antibiotics, especially nitroimi-
dazoles, for treatment of other illnesses (Meyer et al., 2002).    
No antimicrobial agent can cure all H. pylori infected individuals, and even the 
best fails in 5 to 10 percent of cases (Wu and Sung, 1999).  Patient compliance and drug 
resistance are important elements to consider when treating this infection.  Because of 
these factors, readily available, natural, alternative means are being studied to treat H. 
pylori infection.  
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Natural Products for H. pylori Treatment 
Because the effective lifespan of any antibiotic is limited, the search for new an-
timicrobials has risen dramatically in recent years.  In addition, increased public aware-
ness of the overuse/misuse of prescription antibiotics coupled with the desire for greater 
autonomy over personal medical care has led to increased demand for natural, safe alter-
native medications. 
Since H. pylori‘s discovery, numerous studies have investigated naturally occur-
ring substances; mostly of vegetable and plant origin for anti-H. pylori activity.  To date, 
a considerable amount of work has been done screening plant-derived compounds for 
their potential anti-H. pylori applications in vitro (O‘Gara et al., 2000; Malekzadeh et al., 
2001; Bhamarapravati et al., 2003; Bergonzelli et al., 2003; Adeniyi and Anyiam, 2004; 
Krausse et al., 2004; Lin et al., 2005; Ho et al., 2006; Paraschos et al., 2007; Yang et al., 
2008; De et al., 2009; Pastene et al., 2010) and in vivo (Katoaka et al., 2001; Bergonzelli 
et al., 2003; Matsubara et al., 2003; Takabayashi et al., 2004; Ruggiero et al., 2006; da 
Mota Menezes et al., 2006; Gotteland et al., 2008; Lee et al., 2008) as well as beneficial 
microorganisms (e.g. Lactobacilli and Bifidobacterium) frequently consumed in the hu-
man diet (Canducci et al., 2000; Lorca et al., 2001; Chatterjee et al., 2003, Nista et al., 
2004; Linsalata et al., 2004; Wang et al., 2004).  These studies have evaluated a diverse 
variety of plant materials including licorice, cinnamon, cashew apples, mastic gum, gin-
ger, and garlic extracts, along with numerous others with most reporting moderate bacte-
riostatic and/or -cidal activity against H. pylori (Fukai et al., 2002; Tabak et al., 1999; 
Kubo et al., 1999; Gaby, 2001; Iimuro et al., 2002; Chatterjee et al., 2004; O‘Mahony et 
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al., 2005; Gaus et al., 2009).  In addition to reduced cell viability, several studies have 
reported anti-inflammatory, -VacA, -urease, and -adhesive effects; suggesting the possi-
bility of shared cellular targets or mode(s) of action between certain extracts or similar 
classes of constituent compounds (Pastene et al., 2010).  Therefore, even if these sub-
stances do not completely eradicate H. pylori, their use still remains relevant as they may 
be useful in 1) the dietary management/amelioration of disease symptoms or 2) conjunc-
tion with current antibiotic treatments to possibly reduce required dosage levels (Koga et 
al., 2002; Hemaiswarya et al., 2008; Yang et al., 2008).  In addition, it is believed that the 
complexity of bioactive compounds present in these products and their broad range of 
activity over a number of microorganisms may make it difficult for microbes to acquire 
resistance during treatment (Vattem et al., 2005).   
Because of the diversity in plant materials evaluated, most studies prepare extracts 
using different methods and solvents.  Therefore, when available, the use of single puri-
fied compounds has received increased scrutiny in order to eliminate variability.  Extract-
able phenolic phytochemicals such as cinnamic acids, cinnamaldehydes, courmarins, 
phenolic acids, capsaicin, flavonoids and tannins have all shown some anti-H. pylori ac-
tivity with promising results (Vattem et al., 2005).  Berberine, a cationic alkaloid, found 
in goldenseal and Oregon grape was reported as having broad-spectrum antimicrobial 
activity (especially when used alongside multidrug pump inhibitors) (Tegos et al., 2002) 
as well as inhibiting the growth of H. pylori in vitro with moderate suppression in vivo 
(Gaby, 2001).  Kaempferol (a flavonoid), isolated from indigo and also found in a variety 
of other plants, showed anti-H. pylori activity in infected Mongolian gerbils (Katoaka et 
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al., 2001).  Curcumin, the major active constituent in Curcuma longa (i.e. turmeric), was 
recently reported to inhibit several clinical H. pylori isolates and be highly effective in 
eradicating H. pylori from infected mice as well as restoring H. pylori-induced gastric 
damage (De et al., 2009).  Sulforaphane, a compound isolated from broccoli sprouts was 
shown to exert bacteriostatic and -cidal activity against multiple antibiotic-resistant H. 
pylori strains as well blocking gastric tumor formation in mice (Fahey et al., 2002).    
Although these studies demonstrate the effectiveness of individual compounds 
against H. pylori, it is important to note that greatest antimicrobial activity is most likely 
achieved with the least risk of developing drug resistance is most likely achieved using 
combinations of compounds (in purified or natural forms) acting additive-
ly/synergistically and should not be overlooked (Yang et al., 2008; Brown et al., 2009).  
Although many studies report promising findings, most do not reveal the active com-
pounds responsible or the mechanism(s) by which these agents act against H. pylori in 
vitro or in vivo, leaving many questions unanswered (Elattar and Virji, 1999).  Moreover, 
evidence has shown that populations which consume more fruits and vegetables in their 
daily diet do have lower incidences of gastric disease and that this may be in part because 
of natural compounds (phytochemicals) present in these plant materials (Yamada et al., 
1998; Fukai et al., 2002).  In the cancer cascade proposed by Kusters et al. (2006), host 
diet is recognized as a significant contributing factor (along with immune response and 
host genetics) influencing the outcome of H. pylori infection and disease progression. 
Therefore, an inexpensive, diet-based treatment possessing antibacterial, anti-
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inflammatory, and anti-carcinogenic properties (all needed to counteract a multifaceted 
H. pylori infection) would be very appealing. 
Grapes for H. pylori Treatment 
Of the numerous plant-based substances studied to date, grapes are considered a 
promising source of novel antimicrobial agents and a prime candidate for H. pylori treat-
ment/prevention due to their safety, abundance, unique chemical profiles, high structural 
diversity, and extensive biological activity (Mertens-Talcott and Percival, 2005; Harwood 
et al., 2007; Xia et al., 2010).  Grapes (Vitis vinifera) are widely consumed in the United 
States and a part of many popular foods as reported by the National Agricultural Statistics 
Service (2003).  Previous studies have shown that consumption of these foods can inhibit 
carcinogenesis, protect against cardiovascular disease and other oxidation linked diseas-
es, and be effective at inhibiting bacterial growth (Vattem et al., 2005; Steinmetz and Pot-
ter, 1996; Djousse et al., 2004; Jayaprakasha et al., 2003).  In addition, extracts produced 
from grape seeds and pomace are considered waste by the wine and juice industries, so 
these by-products are readily available, inexpensive, and have already been exploited as 
natural antioxidants (Jayaprakasha et al., 2001).   
Grape products contain high amounts of natural antioxidants with levels four to 
five times that of vitamin C or E; both of which were previously found to reduce H. pylo-
ri-induced gastritis in Mongolian gerbils because of their associated antioxidant levels 
(Shi et al., 2003; Sun et al., 2005).  Further, grape seed extracts have continually shown 
better protection against free radicals and DNA damage than vitamins C, E, and β-
carotene (Bagchi et al., 2000).  Antioxidant levels are believed to be important for H. py-
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lori treatment; especially since this organism produces oxygen-free radicals, e.g. superox-
ide anion and hydroxyl radicals; leading to increased oxidative damage and gastric in-
flammation.  The free-radical scavenging ability of the grape extracts may work to pre-
vent this damage (Chatterjee et al., 2004).   
In addition to antioxidant capacity, grapes also possess numerous health-
promoting properties due to their ability to produce large numbers of constituent poly-
phenolic phytochemicals including phenolic acids, flavonoids, and proanthocyanidins 
(Vattem et al., 2005).  These compounds are divisible into single-ring phenolic acids (e.g. 
gallic acid), bisphenols including stilbenes (e.g. resveratrol), tricyclic phenols (e.g. flavo-
noids like rutin and quercetin) and their subclasses, and oligomeric and polymeric species 
(e.g. the proanthocyanidins and anthocyanidins, responsible for the major coloring com-
ponents of red grapes) (Sovak, 2001).  Anthocyanidins are the largest group of phenolic 
compounds consumed in the human diet and are important in maintaining health because 
of strong antioxidant activities with a positive relationship between total phenolic content 
and antioxidant capacity (Velioglu et al., 1998).  The composition and levels of phenolic 
compounds found in grapes are dependent on the cultivar, year of production, geographic 
location, and degree of maturation (Shi et al., 2003).  The color of grape also determines 
phenolic content (Lee and Jaworski, 1987). 
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Figure 1.1. Chemical structures of resveratrol (left) and quercetin (right). 
 
 
All the above molecules are synthesized naturally by the plant through simple 
condensation of phenylalanine in water (Sovak, 2001).  These compounds can be ex-
tracted by different methods; however, organic solvents like ethanol, acetone, and metha-
nol (used alone or in combination) are typically used in place of simple ethanol/water ex-
traction (Sovak, 2001).  Approximately, 60-70% and 28-35% of total extractable phenol-
ics are found in the grape‘s seed and skin, respectively (Shi et al., 2003).  Low levels are 
also found in the pulp; however, these amounts are insignificant relative to the seed and 
skin and are more difficult to extract in large quantities. 
Of the polyphenols, flavonoids are the most extensively studied including querce-
tin (a flavonol in grape skin) and catechin (a flavonol in grape seeds).  Flavonoids are hy-
droxylated phenolic substances occurring as a C6-C3 unit linked to an aromatic ring 
(Cowan, 1999).  Because they are synthesized by plants in response to various stresses 
including microbial infection, it is not surprising that they have been found to be effective 
antimicrobial substances against a wide array or microorganisms (Dixon et al., 1983).  
This activity is believed to be due to their ability to act as antioxidants, suppressing in-
flammation, and ability to complex with extracellular and soluble proteins or bacterial 
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cell walls and components (i.e. surface-exposed adhesins, cell wall polypeptides, and 
membrane-bound enzymes, as described for quinones (another well studied polyphenol in 
St. John‘s wort (Hypericium perforatum)) (Stern et al., 1996; Duke, 1985; Cowan, 1999).  
More lipophilic flavonoids may also disrupt microbial membranes (Tsuchiya et al., 
1996).  In addition, quercetin and green tea catechins have also been reported to inhibit 
DNA gyrase in E. coli by interaction with its ATP binding site (Gradišar et al., 2007) and 
reduce macrophage activation (Ramos et al., 2006; Okoko and Oruambo, 2009). 
Although grapes, related fruits, and their compounds have been studied extensive-
ly for their antioxidant potential, relatively little information is available on the antimi-
crobial properties of grape extracts against H. pylori.  Some studies have shown evidence 
that these products are effective against both Gram-negative and Gram-positive microor-
ganisms (Jayaprakasha et al., 2003; Özkan et al., 2004).  Other fruits such as cranberry 
have also demonstrated antibacterial and more importantly anti-H. pylori activity includ-
ing inhibition of H. pylori adhesion to human gastric mucosa (Vattem et al., 2005; Burger 
et al., 2000) and urease production (Lin et al., 2005).  A study by Dong and Shi (2003) 
reported that cranberry juice reduced H. pylori infection in mice with a clearance rate of 
80%.  In support of this, Zhang et al. (2005) found that approximately 15% of infected 
individuals who consumed cranberry juice for one month were no longer infected with H. 
pylori.  In addition to these findings, various other berry extracts have been shown to in-
hibit H. pylori and even increase the organisms‘ susceptibility to antibiotics when used in 
conjunction with these fruits (Chatterjee et al., 2004).  
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Shi et al. (2003) reported that red wine may have anti-H. pylori properties since it 
contains approximately 63% of the total phenolics from grapes.  Resveratrol, an active 
constituent present in high quantities in red wine was shown to have anti-H. pylori effects 
in addition to being highly anti-carcinogenic with superior superoxide radical trapping 
activity (Daroch et al., 2001; Mahady and Penland, 2000; Mahady and Penland, 2003; 
Jang et al., 1997).   
Some studies have shown that grape/polyphenolic products may also act against 
H. pylori by specifically inhibiting VacA-induced gastric damage.  Tombola et al. (2003) 
reported that red wine and green tea polyphenols inhibited H. pylori VacA-induced ion 
channel formation, urea conduction, and cell vacuolation and that the toxin was inhibited 
equally well at pH 4 or 7 upon exposure to these compounds; supporting their potential 
effectiveness in vivo since they would be unaffected by the stomach‘s high luminal acidi-
ty (Achtman and Suerbaum, 2001).  Flavanoids and flavonoid glycosides were also re-
ported as chemically stable under human stomach conditions, indicating that these prod-
ucts may also be ideal for the treatment of H. pylori infection (Gee et al., 1998).  Later, 
using red wine, green tea, and pure polyphenols (tannic acid, n-propyl gallate, hop bract 
tannin) VacA-intoxicated mice were successfully treated following oral administration of 
VacA toxin (Yahiro et al., 2005; Ruggiero et al., 2006; Ruggiero et al., 2007); supporting 
Tombolo‘s study.  When animals were infected with live H. pylori cells, gastric inflam-
mation and erosion were reduced; however, no significant alternation in H. pylori coloni-
zation was observed, further supporting the hypothesis that VacA may be a key molecular 
target of these compounds (Ruggiero et al., 2006). 
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In addition to toxin inhibition, attachment of H. pylori to gastric epithelial cells 
may also be influenced by these compounds.  Although the exact mechanism for this is 
currently unknown, it is hypothesized that it may be due to the high antioxidant activity 
generated by anthocyanins contained in the plant material (especially grape skins).  This 
may be accurate since proanthocyanidin extracts from cranberries were previously found 
to decrease P-fimbriated Escherichia coli to uroepithelial-cell surfaces, possibly correlat-
ing with H. pylori (Howell et al., 1998).  Procyanidins may also inhibit free radical pro-
duction associated with inflammatory reactions by interacting with the synthesis and re-
lease of proinflammatory substances like histamine and leukotrienes and also hyaluroni-
dase, an enzyme associated with tissue damage during inflammation (Hansen, 1995; 
Pearce et al., 1984).    
Muscadine Grapes for H. pylori Treatment 
Muscadine grapes (Vitis rotundifolia) are native to the southeastern United States 
and can grow in warm, humid climates where Vitis vinifera do not grow as well.  This 
grape type has significantly higher total phenolic contents than Vitis vinifera; distin-
guished by high ellagic, gallic, and flavonoid glycoside concentrations along with unique 
anthocyanin chemistries (Greenspan et al., 2005).  Extremely high antioxidant activity 
has also been reported for muscadines (Patrana-Bonilla et al., 2003).  In addition, musca-
dine grapes and their phenolics have shown strong anti-inflammatory and anticancer 
properties when tested in mice and with various cancer cell lines (Greenspan et al., 2005; 
Weiguang, et al., 2005).  Furthermore, muscadine juice and phenolic extracts were re-
cently reported to have significant antibacterial activity against Salmonella, Listeria, and 
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Cronobacter strains (Kim et al., 2010; Park et al., 2011).  Although not extensively stu-
died in relation to other grape types, muscadines are believed to not only possess more 
desirable properties (e.g. higher antioxidant and phenolic contents) but are superior to 
Vitis vinifera at inhibiting H. pylori as found in a recent study comparing these two grape 
types (Brown et al., 2009).  
In addition to other studies reporting the antimicrobial and anti-H. pylori proper-
ties of phenolic compounds (Fahey et al., 2002; Mabe et al., 1999; O‘Gara et al., 2000; 
Vattem et al., 2005; Yahiro et al., 2005), we have previously shown in our laboratory that 
phenolic-containing muscadine grape extracts may help weaken H. pylori adhesion to 
host cell surfaces or reduce cellular damage caused by this bacterium (Brown et al., 2009; 
Burger et al., 2000; Yahiro et al., 2005).  Compounds such as ellagic acid and quercetin, 
high in some grape varieties, have also been shown to possess anti-cancer activities and 
reduce gastric epithelial cell death by inhibiting H. pylori VacA toxin (Smith et al., 2004; 
Shin et al., 2005).   
Rationale for Our Study 
Muscadine grapes contain approximately five times the levels of total phenolic 
compounds as commercial red grapes (Pastrana-Bonilla et al., 2003).  They are readily 
available, have no known toxicity, and no side effects.  Muscadine grapes also contain 
many unique forms of compounds which may be effective, alone or in combination, in 
the dietary management of H. pylori infection as determined in previous studies con-
ducted in our laboratory.  We have previously demonstrated that muscadine grape ex-
tracts have significant but varied effects on H. pylori infection.  Analysis of green fluo-
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rescent protein-labeled H. pylori using confocal laser scanning microscopy revealed re-
duced attachment of the bacterium to host cell surfaces following treatment.  Further-
more, earlier in vitro and in vivo studies suggest virulence factors associated with this or-
ganism (e.g. VacA) may be suppressed (as determined by MTS cell proliferation assays) 
following treatment with grape extracts or major phenolic compounds (Brown et al., 
2009).  However, additional factors are also believed to be affected.  These results are in 
agreement with previous studies reporting reduced gastritis (linked to VacA) following 
administration of purified polyphenolic compounds or red wine to infected mice (Ruggie-
ro et al., 2006; Ruggiero et al., 2007).  In addition, anti-inflammatory responses may be 
responsible for reduced host cell damage as indicated by an animal study in which H. py-
lori-infect guinea pigs showed reduced H. pylori counts, gastric inflammation, and lipid 
peroxidation following administration of quercetin (Gonzalez-Segovia et al., 2008). 
Since muscadine grapes are inexpensive, easily handled, and non-toxic, it is be-
lieved that consumption of the entire fruit or its extracted constituents may be beneficial 
to human health and an effective strategy for H. pylori treatment or prevention.  An add-
ed benefit may be that these bioactive compounds may help limit erosion of the gastric 
mucosa caused by continuous inflammation (Greenspan et al., 2005).  In addition, higher 
compliance and little to no side effects would further entice patients to be more accepting 
of treatment and complete prescribed therapies and not inadvertently select for antibiotic 
resistance by ending treatment prematurely.  Finally, many of these compounds may be 
difficult for H. pylori to develop resistance against because of their suspected synergistic 
interactions and unique cellular targets; however, the means by which muscadine grapes 
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and their constituent compounds exert these effects have yet to be determined (Vattem et 
al., 2005).   
Because of the available literature supporting the potential antimicrobial applica-
tions of grape products and associated compounds, as well as previous studies conducted 
in our laboratory, we believe that muscadine grape extracts and their chemical constitu-
ents may be beneficial in the treatment of H. pylori infection.  Results from this study 
will not only provide valuable information on the therapeutic potential of muscadine 
grapes and related compounds against H. pylori, but also provide novel insights into the 
overall methodology for evaluating other natural compounds against H. pylori in the fu-
ture.  
The objectives of this study are to 1) determine the major phenolic compounds 
present in muscadine grape skin extracts responsible for anti-H. pylori activity 2) eluci-
date their possible mode(s) of action in vitro and 3) evaluate muscadine grape skin and 
these compounds as a prerequisite to the development of a diet-based strategy used to at-
tenuate the disease process in vivo. 
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CHAPTER TWO 
ACTIVITIES OF MUSCADINE GRAPE SKIN AND QUERCETIN 
AGAINST HELICOBACTER PYLORI INFECTION IN MICE 
 
Abstract 
The aim of this study was to explore the preventative potential of muscadine 
grape skin and the single flavonoid, quercetin, as an alternative means for ameliorating H. 
pylori infection and/or the H. pylori-induced inflammatory response in mice. 
The antimicrobial and anti-inflammatory properties of muscadine grape skin and 
quercetin, a major phenolic constituent, were evaluated against H. pylori in vitro and in 
vivo.  The antimicrobial activity of quercetin was evaluated against 11 H. pylori strains in 
vitro with inhibition of all strains at 128 - 64 µg/ml.  In vivo studies showed a moderate 
reduction in H. pylori counts following treatment with 5 and 10% muscadine grape skin 
or quercetin (25 mg/kg body wt) in addition to significantly reduced inflammatory cyto-
kines (TNF-α, IL-1β, and IFN-γ) as compared to untreated mice. 
Muscadine grape skin and quercetin did not significantly reduce H. pylori growth 
in a mouse model.  However, these products were effective in regulating the inflammato-
ry response to H. pylori infection. 
Our results suggest that H. pylori infection may be reduced or prevented via the 
consumption of fruits rich in certain phenolic compounds (e.g. quercetin) such as musca-
dine grapes. 
 
 
 
 
45 
 
Introduction 
 
Infection with Helicobacter pylori can result in chronic gastritis, peptic ulcer dis-
ease, and an increased risk of developing mucosa-associated lymphoid tissue (MALT) 
lymphoma and gastric cancer (Cover and Blaser, 1995).  Although this pathogen coloniz-
es more than half the world‘s population, making it one of the most common bacterial 
infections in humans, only a subset of those infected display symptoms (Osaki et al., 
1998).  The severity of H. pylori infection is dependent on multiple factors like bacterial 
strain(s), age of acquisition, and immune response.  Disease progression may also be in-
fluenced by additional factors such as host environment and diet.  Host dietary factors in 
particular are thought to play a significant role in H. pylori disease outcome, especially 
during and immediately following colonization (Testerman et al., 2001). 
It is well-documented that high-salt diets correlate with gastritis and gastric can-
cer and enhance the probability of developing severe disease following H. pylori infec-
tion.  In support of this, high sodium chloride consumption has been found to alter H. py-
lori growth and increase expression of cagA and vacA genes in vitro, both encoding tox-
ins key in H. pylori virulence (Gancz et al., 2008; Loh et al., 2007).  In addition, people 
consuming salty foods may even enhance H. pylori colonization (Tsugane et al., 1994, 
Fox et al., 1999).  On the other hand, people who consume more fruits and vegetables 
have a reduced risk of H. pylori infection and/or developing upper gastrointestinal dis-
orders and related symptoms (Buiatti et al., 1990; Singh and Gaby, 1991).  The means by 
which this protective effect occurs is currently unknown but may be associated with 
higher intake of bioactive compounds possessing strong antibacterial and antioxidant ac-
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tivities (Tombola et al., 2003; O‘Gara et al., 2000; Yahiro et al., 2005; Zhang et al., 1997; 
Bennedsen et al., 1999).  Compounds present in these foods may act against H. pylori by 
reducing bacterial growth and/or interfering with attachment and/or virulence factors (e.g. 
urease, VacA, CagA).  These compounds may also counteract destructive autoimmune-
induced tissue damage via suppression of Th1 pro-inflammatory cytokines (e.g. IFN-γ, 
TNF-α) and associated oxidative damage triggered by H. pylori infection (Chatterjee et 
al., 2004; Ruggiero et al., 2006; Ruggiero et al., 2007). 
Muscadine grapes (Vitis rotundifolia) are common in the southeastern U.S. and 
are characterized by their unique anthocyanin profiles and high flavonoid concentrations; 
contributing to their extremely high antioxidant levels and strong anti-inflammatory and 
anticancer potentials (Greenspan et al., 2005; Pastrana-Bonilla et al., 2003; Weiguang et 
al., 2005).  Quercetin (3, 3′, 4′, 5, 6-pentahydroxyflavone) is a naturally-occurring dietary 
flavonol found in muscadine grape skin (Kühnau, 1976).  Because of its high antioxidant 
capacity and anti-H. pylori potential, it was chosen for use in this study.   In addition, 
these products are inexpensive, non-toxic, and previously shown to possess antibacterial 
properties; therefore, the fruit itself or its extractable chemical constituents may serve as 
an effective supplement for H. pylori suppression or treatment.  
The objective of this study was to explore the preventative potential of muscadine 
grape skin and the single flavonoid, quercetin, as an alternative means for ameliorating H. 
pylori infection and/or the H. pylori-induced inflammatory response in mice. 
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Materials and Methods 
 H. pylori.  Eleven H. pylori strains were used in this study.  H. pylori strains G2-
1, 26695, WV99, NB2-1 and 1324P-1 were obtained from Dr. Douglas Berg (Washing-
ton University, St. Louis, MO).  H. pylori strains D5251, D5131, D5178, D5136, and 
D5135 were obtained from Dr. Ben Gold (Emory University and Centers for Disease 
Control and Prevention, Atlanta, GA).  H. pylori SS1, a mouse-adapted strain, was pro-
vided by Dr. Kathryn Eaton (Department of Veterinary Biosciences, Ohio State Universi-
ty, Columbus, OH).  H. pylori 26695, G2-1, 1324P-1, D5251, D5131, D5178, and SS1 
were positive for the cagA gene, while all strains were vacA positive.  Bacteria were 
grown on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, MI) (pH 7.4 ± 0.2) 
supplemented with 7% horse serum (HS) (Sigma Chemical Co., St. Louis, MO) at 37°C 
for 72 h under microaerophilic conditions (5% O2, 10% CO2, and 85% N2) in a GasPak 
jar (BBL Microbiology Systems, Cockeysville, MD) (Jiang and Doyle, 2000). 
For the animal challenge study, H. pylori SS1 was grown under the same condi-
tions at 37 °C for 72 h.  Plate growth was used to inoculate 30 ml of BHI broth (BHIB) in 
sterile media bottles.  Cultures were then incubated overnight under the same conditions 
with shaking at 120 rpm.  Cells were harvested by centrifugation at 3,500 x g for 5 min 
and resuspended in sterile BHIB for the animal challenge.  Prior to infection, cultures 
were examined microscopically to confirm purity and motility.  Serial dilutions of each 
inoculum were plated in triplicate onto antibiotic supplemented plates of BHI agar con-
taining 7% HS and Dent antibiotic supplement [vancomycin (10 µg/ml), trimethoprim (5 
µg/ml), cefsulodin (5 µg/ml), and amphotericin B (5 µg/ml)] (Oxoid, Basingstoke, 
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Hampshire, UK) and onto Tryptic Soy Agar (TSA) with 5% sheep blood (bioMérieux, 
Inc., Durham, NC) to confirm inoculum concentration and purity. 
Anti-H. pylori activity of quercetin.  For antimicrobial susceptibility testing, H. 
pylori was grown under the previously described conditions and spot-inoculated (ca. 1 x 
10
5
 CFU/spot) onto pre-warmed BHI-HS agar containing 4.0 to 256 µg/ml quercetin 
(Sigma) in triplicate.  Quercetin was prepared in dimethyl sulfoxide (DMSO) (MP Bio-
medicals, Solon, OH) and filter sterilized.  Plates containing DMSO were used as a sol-
vent control.  The minimal inhibitory concentration (MIC) was determined as the lowest 
concentration required to completely inhibit the growth of H. pylori following 1 week 
incubation under microaerophilic conditions. 
Animals.  Six-week old, female, C57BL/6 mice were obtained from Jackson La-
boratories (Bar Harbor, ME).  All animals were specific-pathogen free and clear of H. 
pylori upon receipt.  Mice were housed in groups of four in microisolater cages and fed a 
conventional rodent diet (Harlan Teklad, Madison, WI) with or without muscadine grape 
skin (MGS) powder [5 and 10% (w/w)] (Muscadine Products Corporation, Wray, GA) 
and sterile water ad libitum.  Mice receiving quercetin alone were fed a non-
supplemented diet.  Quercetin treats (25 mg/kg body weight) (approximately 0.5 
mg/mouse) were prepared by Bio-Serv (Frenchtown, NJ) and administered once daily.  
All diets were begun 1 week prior to infection with H. pylori.  All procedures were ap-
proved by the Clemson University Institutional Animal Care and Use Committee. 
Mice challenge study.  Mice were fasted for 4 h and then orally administered 0.1 
ml of sterile 0.5 M sodium bicarbonate (Fisher Scientific, Norcross, GA) immediately 
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prior to inoculation with H. pylori.  Each mouse received 0.25 ml (10
7
 to 10
8
 
CFU/mouse) of H. pylori suspension by oral gavage using a 24 gauge needle; excluding 
the no H. pylori controls which received sterile BHIB.  Mice were challenged three times 
at two day intervals over a 5-day period.  In order to monitor H. pylori infection status 
throughout the study, a sensitive, non-invasive PCR assay was used.  Following H. pylori 
infection, cages were changed weekly (i.e. mice transferred to new sterile cages contain-
ing fresh, sterile bedding, food, and water) and feces were collected using sterile forceps.  
Feces were kept frozen at -20 ºC until analysis.  At 10 weeks post infection (p.i.), mice 
were anesthetized with Isoflurane and killed by cervical dislocation.  A heart puncture 
was performed on each animal and serum was collected and stored at -80 ºC.  Stomachs 
were aseptically removed and bisected along the greater and lesser curvatures with one-
half used for H. pylori enumeration and the other immediately preserved in neutral buf-
fered formalin for histological evaluation.   
One-half of each stomach was weighed and immersed in brucella broth (BB) 
(Difco Laboratories, Detroit, MI) containing 10% HS.  The tissue was homogenized us-
ing Dounce tissue grinders (1 ml) (Wheaton Industries, Inc, Millville, NJ) and serially 
diluted in phosphate-buffered saline (PBS) (pH 7.4).  Tissue grinders were cleaned be-
tween samples by rinsing twice with 75% ethanol and then sterile BB.  One-hundred mi-
croliters of each dilution were then spread-plated onto selective medium: BHI agar sup-
plemented with 5% defibrinated sheep blood (Remel, Lenexa, KS), vancomycin (100 
µg/ml), polymyxin B (3.3 µg/ml), bacitracin (200 µg/ml), amphotericin B (50 µg/ml), 
and nalidixic acid (10.7 µg/ml) (Sigma, St. Louis, MO).  Plates were incubated microae-
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robically at 37 ºC for 7 days.  The identity of H. pylori was confirmed by Gram stain, 
oxidase, and catalase tests.  Colonies were counted and expressed as CFU/g tissue. 
DNA extraction and purification.  H. pylori DNA was extracted from fecal 
samples using an UltraClean fecal DNA extraction kit from MO BIO Laboratories, Inc. 
(Carlsbad, CA) following the manufacturer‘s directions.  To eliminate PCR inhibitors not 
removed during DNA extraction from fecal material, a modified approach of that de-
scribed by Monteiro et al. (2001) was used.  Briefly, after initial DNA extraction, 10 µl of 
DNA was electrophoresed in 1.5% (wt/vol) agarose gels in Tris-borate-EDTA (TBE) buf-
fer at 50 V for 3 h.  Following staining with ethidium bromide, DNA bands were excised 
with sterile scalpels and cleaned using an UltraClean GelSpin DNA purification kit (MO 
BIO Laboratories, Inc., Carlsbad, CA).  Purified DNA was then used for subsequent 
PCRs. 
PCR.  PCR assays targeting the 16S rRNA gene were performed as described by 
Chisholm et al. (2001).  Briefly, 20 µl reaction mixtures containing 2 µl of extracted 
DNA, 1.5 mM MgCl2, 200 µM (each) dNTPs, 0.4 µM (each) primer HP1 (5′-CTG GAG 
AGA CTA AGC CCT CC) and HP2 (5′- ATT ACT GAC GCT GAT TGT GC), 1 U Taq 
polymerase in PCR buffer, was held for 5 min at 95 ºC, followed by 35 cycles of 30 sec 
each at 95 ºC, 60 ºC, and 72 ºC, and by 5 min. at 72 ºC.  The amplification of a 110-bp 
fragment was confirmed by electrophoresis.   
Histological evaluation.  One half of each stomach was washed vigorously in 
sterile PBS, fixed in 10% buffered formalin, and sent to the Clemson University Veteri-
nary Diagnostic Center, Columbia, SC for processing and evaluation.  Samples were 
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stained with hematoxylin and eosin (HE) and modified Giemsa stain.  All tissues were 
blindly scored by two pathologists based on the updated Sydney system (Dixon et al., 
1996). 
ELISA.  Mouse stomach tissue homogenate and serum samples were analyzed by 
sandwich enzyme-linked immunosorbent assay (ELISA).  Cytokines evaluated were tu-
mor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ) and interleukin-1 beta (IL-
1β).  All samples were tested in duplicate following the manufacturer‘s instructions 
(eBioscience, Sandiego, CA).  Total protein was measured by the Bradford method.  
Plates were read at 450 nm using a BioTek µQuant microplate spectrophotometer (Biotek 
Instruments, Inc., Winooski, VT).  Cytokine levels were expressed as pg/ml of serum or 
pg/mg of total protein. 
Statistical Analysis.  The mean values of H. pylori cell count and ELISA data 
were submitted to one and two-way analysis of variance (ANOVA) and Tukey‘s tests to 
determine differences among treatments.  All values were considered statistically signifi-
cant at P < 0.05 using SAS 9.1 software (SAS Institute Inc., Cary, NC). 
Results 
Antibacterial Activity of Quercetin Against H. pylori in vitro.  Following anti-
microbial susceptibility testing, all 11 H. pylori strains were determined to be sensitive to 
quercetin at concentrations ranging from 64 to 128 µg/ml (Table 2.1).  DMSO had no ef-
fect on any of the strains tested. 
Anti-H. pylori Activity in vivo.  Mice were fed MGS (5 or 10% w/w) or querce-
tin (25 mg/kg) daily with infection status monitored weekly by PCR (eliminating the pos-
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sibility of transient H. pylori infection).  Final quercetin concentrations in treats were ap-
proximately 10 fold greater than quercetin levels previously determined in MGS powders 
(approximately 57 µg/g MGS dry weight) (unpublished data).  After 10 weeks, H. pylori 
was still present in all treatment groups as detected by PCR, culturing and histological 
analysis. All mice (n=21) inoculated with H. pylori were successfully infected and re-
mained colonized throughout the study as revealed by weekly analysis of stool samples 
by PCR (Figure 2.1).  Of the mice given diets supplemented with MGS or quercetin, most 
showed a moderate reduction in H. pylori with cell counts ranging from 7.3 x 10
5
 to 5.8 x 
10
6
 CFU/g of stomach tissue respectively, as compared with 1.7 x 10
7
 CFU/g in no 
treatment controls (P > 0.05) (Table 2.2). 
 Anti-inflammatory Activity of Muscadine Grape Skin and Quercetin.  Cyto-
kines commonly associated with H. pylori-induced inflammation were tested to deter-
mine any effect diets supplemented with MGS (5% and 10%) or quercetin (~25 mg/kg 
body weight) had on reducing the inflammatory response.  Following treatment with 
MGS, both IFN-γ and IL-1β levels were significantly reduced (P < 0.05) in infected mice 
(Figure 2.2).  A dose-dependent response was observed when mice were fed either 5% or 
10% MGS.  TNF-α levels were also reduced (P < 0.05) following treatment, with unin-
fected and those receiving 10% MGS showing similar results with both below detection 
limits.  Quercetin, when given alone to infected animals reduced IL-1β levels (P < 0.05) 
but did not lead to a significant reduction in TNF-α or IFN-γ (P > 0.05) in serum samples.  
In contrast, all cytokine levels were significantly reduced (P < 0.05) in gastric tissue ho-
mogenates of treated mice.   
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The majority of tissues sampled from the infected control group displayed mod-
erate to diffuse infiltration of lymphocytes, plasma cells, neutrophils and eosinophils in 
the lamina propria with infiltrates especially intense at the submucosa interface (Figure 
2.3).  One control animal infected with H. pylori showed mild to moderate atrophy of 
chief cells accompanied by mucous metaplasia of cells in some gastric glands.  Mice fed 
10% muscadine grape skin showed no significant cellular atrophy with the antrum and 
corpus only mildly infiltrated by lymphocytes, plasma cells and fewer eosinophils despite 
containing relatively high numbers of H. pylori cells.   
Discussion 
Because of the rise in antimicrobial resistance, an inexpensive, diet-based treat-
ment against H. pylori infection would be of great interest.  Numerous studies have ex-
amined the activities of natural, plant-based extracts and compounds against H. pylori in 
vitro; however, few have reported in vivo efficacy.  We have previously shown that MGS 
extracts and their constituent polyphenolic compounds are capable of significantly reduc-
ing H. pylori growth in vitro and may affect bacterial attachment to host gastric cells, a 
key step in H. pylori colonization/virulence (Brown et al., 2009). 
In this study, we aimed to determine if a diet supplemented with MGS or querce-
tin, the third highest major phenolic in MGS (Greenspan et al., 2005; Brown et al., 2009), 
could reduce or eliminate H. pylori from infected mice or protect against H. pylori-
induced oxidative damage. 
In vitro findings showed that quercetin inhibits the growth of all tested H. pylori 
strains suggesting that it may also be effective in vivo.  Agar dilution results are in 
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agreement with our previous study (Brown et al., 2009) in which muscadine grape skin 
and seed extracts, as well as pure constituent compounds (e.g. resveratrol, ellagic acid) 
were found to be effective against the same H. pylori strains; suggesting that these com-
pounds may work synergistically or additively against H. pylori.  
  Although H. pylori was not eradicated following treatment, bacterial numbers 
were lower (0.4 to 1.2 logs) in treatment groups as compared to infected controls; sup-
porting a dose-dependent, albeit weak, antibacterial response.  These findings are in 
agreement with similar studies in which other polyphenols failed to completely eradicate 
H. pylori when administered to infected animals while showing moderate reduction in H. 
pylori numbers (Ruggiero, 2006; Ruggiero, 2007).  Quercetin, when given alone to in-
fected animals, resulted in a decline in H. pylori counts similar to that seen in animals fed 
10% MGS.  This was surprising since an earlier hypothesis was that a synergistic action 
between phenolic compounds present in MGS may be necessary to effectively inhibit H. 
pylori growth in vivo.  However, quercetin levels were higher in treats than those deter-
mined from MGS powder.  This may suggest that quercetin, when administered alone at 
relatively high concentrations, may be equally effective in reducing H. pylori as 10% 
MGS.  In support of this, González-Segovia et al. (2008) recently reported that quercetin 
significantly decreased H. pylori colonization in infected guinea pigs.  However, the do-
sage of quercetin used in that study was four-fold higher than ours and directly adminis-
tered twice a day for two weeks.  Therefore, differences in H. pylori levels following 
treatment may be explained by higher quercetin concentrations.  However, comparisons 
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between the two studies could not be made since no plate-count data was available and 
different animal models and H. pylori strains were used. 
On the other hand, the anti-inflammatory properties of MGS appeared to be more 
notable, with gastritis in MGS treated animals only moderately higher than uninfected 
controls in addition to much reduced inflammatory cytokine levels.  In animal models, 
both MGS and quercetin inhibited the induction of gastric damage from H. pylori infec-
tion as shown by ELISA and histological analyses.  These findings are in agreement with 
other studies in which polyphenolic compounds from red wine and green tea were found 
to reduce overall gastritis in H. pylori infected animals while only moderately reducing 
bacterial load (Ruggiero et al., 2006).  Although not tested in this study, the fact that 
MGS and quercetin reduced gastritis while only marginally affecting bacterial coloniza-
tion may further support the protective nature of certain phytochemicals in vivo may be 
linked to VacA, CagA, or urease inhibition.  In addition, the inherent anti-inflammatory 
activities of certain compounds aimed against destructive H. pylori-induced host inflam-
matory responses cannot be excluded (Ruggiero et al., 2006; Gonzalez-Segovia et al., 
2008; Singh and Baby, 1991).  Alternatively, MGS or quercetin may affect H. pylori 
growth by reducing iron availability, decreasing bacterial membrane stability, or inhibit-
ing attachment mechanisms (Guo et al., 2007; Burger et al., 2000).   
 In this study, cytokine levels also appeared to be in agreement with gastric pa-
thologies observed in stomach tissue samples with TNF-α, IL-1, and IFN-γ significantly 
lower in groups fed MGS (P < 0.05).  Although quercetin was unable to significantly re-
duce TNF-α and IFN-γ levels in serum; it did reduce local cytokine levels in infected 
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stomach tissues.  This may suggest that quercetin alone is insufficient in reducing in-
flammation and that a synergistic interaction may be taking place among phenolic com-
pounds contained in MGS or quercetin‘s low bioavailability in its given form.  Reduction 
in these inflammatory mediators may be due to decreased neutrophil leukocyte infiltra-
tion and associated free radical production.  Decreased TNF-α and IL-1β production may 
result in reduced NF-kappaB levels, further contributing to the anti-inflammatory proper-
ties of MGS; however, additional factors cannot be excluded (Gonzalez-Segovia et al., 
2008; Min et al., 2007; Ruiz et al., 2007). 
In a previous study conducted in our laboratory, we reported that MGS extracts 
may also be effective at preventing and/or reducing H. pylori infection via inhibition of 
bacterial attachment mechanisms (Brown et al., 2009).  Although H. pylori was able to 
successfully colonize mice; animals were given MGS for only one week prior to being 
challenged and fasted before infection which may have only slightly weakened the initial 
attachment of H. pylori to gastric epithelium.  In addition, in previous experiments, high-
ly concentrated MGS extracts were used, possibly resulting in a different observable ef-
fect.  
In conclusion, both MGS and quercetin slightly inhibited H. pylori growth while 
significantly reducing inflammation and gastric damage in H. pylori-infected mice.  
Therefore, MGS and/or quercetin may be useful in preventing some of the gastric pathol-
ogies associated with H. pylori infection; however, further studies are necessary to de-
termine MGS and quercetin‘s long-term applications for the prevention or treatment of H. 
pylori infection. 
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Figure Legend 
 
FIGURE 2.1. PCR amplification of H. pylori SS1 16S rRNA gene from H. pylori-
infected control mice feces.  Lane 1, 50-bp DNA size marker (Promega Corp., Madison, 
WI); lane 2, negative control (no DNA template); lanes 3 to 12, DNA extracted from 
mice feces collected at week 1 to 10 p.i., respectively. 
 
FIGURE 2.2. Mice IFN-γ, IL-1β, and TNF-α levels following treatment with 5 or 10% 
muscadine grape skin (MGS) powder or quercetin (25 mg/kg body weight). Panel A, se-
rum (pg/ml).  Panel B, supernatants of gastric tissue homogenates (pg/mg protein).  Error 
bars represent standard error.  The same letter represents no significant difference (P > 
0.05) among treatments.   
 
FIGURE 2.3.  Representative images of HE-stained sections of mouse gastric antrum 
mucosa.  A, negative control (i.e. no H. pylori); B, positive control (i.e. H. pylori with no 
treatment); C, H. pylori-infected mice receiving 10% muscadine grape skin powder.  
Mice infected with H. pylori showed an influx of inflammatory cells at the submucosa 
interface (arrowheads) whereas mice fed 10% MGSP were similar to no H. pylori 
controls.  Scale bars, 50 µm. 
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TABLE 2.1. Minimal inhibitory concentrations of quercetin on H. pylori growth by agar 
dilution assay. 
 
 H. pylori strains 
Conc. 
(μg/ml) 
 
26695 
 
G2-1 
 
WV99 
 
NB2-1 
 
1324P-1 
 
D5251 
 
D5131 
 
D5178 
 
D5136 
 
D5135 
 
SS1 
256   –* – – – – – – – – – – 
128 – – – – – – – – – – – 
64 + – – – – – – – + + – 
32 + + + + + + + + + + + 
16 + + + + + + + + + + + 
8 + + + + + + + + + + + 
4 + + + + + + + + + + + 
Control + + + + + + + + + + + 
 
* –, no growth; +, growth.   
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TABLE 2.2. Effects of muscadine grape skin powder on H. pylori infection in C57BL/6 
mice. 
 
Treatment/diet Mice infected log CFU/g Gastritis score
b
  
no H. pylori control 0/6 ND
 a
 0.5 
H. pylori control 3/3 7.2 ± 0.1 a 2.3 
10% MGSP  7/7 5.9 ± 0.3 a 1.0 
5% MGSP 7/7 6.8 ± 0.4 a — 
Quercetin  4/4 5.9 ± 0.5 a            — 
 
a
 ND, not detected.  The same letter within the column represents no significant difference (P > 0.05) 
among treatments.  
b For gastritis scoring, ―0‖ = no inflammation; ―1‖ = mild inflammation; ―2‖ = moderate inflammation; ―3‖ 
= severe inflammation, and ―-‖ not tested.   
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CHAPTER THREE 
ACTIVITIES OF MUSCADINE GRAPE SKIN AND POLYPHENOLIC 
CONSTITUENTS AGAINST HELICOBACTER PYLORI IN VITRO 
Abstract 
The inhibitory effects of quercetin and resveratrol, active polyphenols identified 
in muscadine grape skin (MGS) extracts, against Helicobacter pylori were investigated.  
Quercetin and resveratrol significantly reduced H. pylori growth regardless of pH (neutral 
and acidic) with minimal bactericidal concentrations (MBCs) of 256 and 128 µg/ml, re-
spectively, while displaying synergistic activity when in combination.  MGS extracts dis-
played the highest efficacy suggesting additional unidentified compounds not detected in 
this study.  Time course viability experiments and phase-contrast microscopy showed a 
dose-dependent anti-H. pylori response to quercetin and resveratrol.  Interestingly, nei-
ther quercetin nor resveratrol affected H. pylori outer membrane integrity as determined 
by 1-N-phenylnapthylamine (NPN) uptake assays.  However, quercetin was found to en-
ter H. pylori as determined by HPLC analysis supporting intracellular drug accumulation.  
The anti-H. pylori effects of quercetin and resveratrol, alone and in combination, suggest 
that these compounds may be useful in the dietary prevention and/or treatment of H. py-
lori infection. 
Introduction 
Helicobacter pylori is a well-known human pathogen and the etiology of various 
gastric diseases including peptic ulcers, gastritis, and stomach cancer (Cover and Blaser, 
1995; Dunn et al., 1997).  While infection is common, disease outcome is likely multifac-
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torial with virulence of infecting strain, host age, genetic constitution, and environment 
all contributing to disease progression (Bergonzelli et al., 2003).  Because of the com-
plexity of H. pylori infection, all possible host/pathogen interactions should be consi-
dered.  One important factor frequently underplayed is host dietary habits which may 
serve a more important role during and immediately following infection with H. pylori 
than previously thought (Testerman et al., 2001).  Some studies have explored the link 
between H. pylori infection and host diet/nutrition with several associating high-salt diets 
with increased risk and/or extent of disease (Tsugane et al., 1994; Fox et al., 1999; Willis 
et al., 1999; Gancz et al., 2008).  On the other hand, consumption of fruits and vegetables 
rich in certain vitamins, antioxidants, and constitutive bioactive compounds (e.g. phyto-
chemicals) has been shown to significantly reduce the incidence of H. pylori infection 
and/or ameliorate associated symptoms (Buiatti et al., 1990; Zhang et al., 1997, Benned-
sen et al., 1999, Yamada et al., 1998; Fukai et al,. 2002, Yanaka et al., 2009).   
Although many strains of H. pylori are susceptible to most currently used antibio-
tics (e.g. clarithromycin, metronidazole, amoxicillin) in vitro, treatment is increasingly 
challenging due to antibiotic resistance and reinfection in certain groups.  Therefore, nov-
el, diet-based therapeutics for use where conventional antibiotic therapies have failed, are 
unavailable, and/or expensive have received considerable attention.   
Numerous studies have investigated naturally occurring plant-derived substances as po-
tential alternatives for H. pylori prophylaxis or treatment (O‘Gara et al., 2000; Bergonzel-
li et al., 2003; Lin et al., 2005; Paraschos et al., 2007; Yang et al., 2008; De et al., 2009; 
Pastene et al., 2010).  In particular, studies have shown that grape polyphenols have 
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strong anti-H. pylori activity; inhibiting growth (Mahady and Penland, 2000; Mahady et 
al., 2003) while reducing H. pylori- and vacuolating cytotoxin-induced gastritis in animal 
models (Tombola et al., 2003; Yahiro et al., 2005; Ruggiero et al., 2006; Ruggiero et al., 
2007).  We have previously reported that muscadine grapes (Vitis rotundifolia) are a val-
uable source of anti-H. pylori compounds with activity against multiple strains in vitro 
and in vivo with effects most likely due to major phenolic compounds (i.e. ellagic acid, 
myricetin, quercetin, trans-resveratrol, gallic acid) acting alone or in synergy (Brown et 
al., 2009; Brown et al., 2010).  Polyphenols are naturally found in fruits and vegetables, 
especially grapes; however, the combination of ellagic acid, quercetin, and resveratrol is 
unique to muscadine species which may suggest that these compounds are largely re-
sponsible its reported biological activities (Mertens-Talcott and Percival, 2005). 
Our earlier studies demonstrating the effectiveness of muscadine grapes and the 
pure flavonoid quercetin against H. pylori prompted us to further explore these products.  
The objective of this study was to identify active phenolic constituents in muscadine 
grape skin (MGS) extracts and determine if any synergism exists among compounds 
while further exploring their anti-H. pylori potential in vitro.   
Materials and Methods 
Chemicals. Pure standards of ellagic acid, gallic acid, myricetin, quercetin, trans-
resveratrol and amoxicillin were purchased from Sigma-Aldrich (St. Louis, MO).  Dime-
thyl sulfoxide (DMSO), ethanol, acetonitrile, methanol, acetic acid, EDTA, and water 
(HPLC grade) were purchased from Fisher Scientific (Norcross, GA). 
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Muscadine grape skin extraction. Four muscadine grape cultivars, namely, two 
purple (Carlos and Woodruff) and two bronze (Noble and Cowart) provided by the Clem-
son University Pee Dee Research and Education Center (Florence, SC) were used in this 
study.  Fresh muscadine grapes were washed in distilled water to remove debris.  Skins 
were collected and dried in a gravity convection oven (Fisher Scientific, Gaithersburg, 
MD) at 60 °C for 24 h, and ground into a fine powder.  A modified method of Jayapraka-
sha et al. (2003) was used for extraction of total phenolics.  Briefly, 5 ml of ace-
tone:water:acetic acid (90:9.5:0.5, v/v/v) was added to 1 g dried MGS each in 10 ml 
screw-capped glass tubes, vortexed for 30 sec, and incubated in a 60 °C waterbath for 8 h 
with shaking.  Samples were centrifuged at 4,500 x g for 10 min to remove debris.  The 
supernatant was collected and the solvent was removed using a SpeedVac (Thermo Fish-
er Scientific, Waltham, MA) at 43 °C.  Dried extracts were stored at -80 °C under nitro-
gen or resuspended in DMSO and used immediately.   
Total phenolics determination. The Folin-Singleton colorimetric method was 
used to determine total soluble phenolic content in the extracts (Singleton and Rossi, 
1965).  Two hundred microliters of appropriately diluted extract were mixed with Folin-
Ciocalteu phenol reagent (1:10, v/v).  After 3 min, 800 µl of 7.5% Na2CO3 was added to 
the reaction mixture, vortexed for 5 sec., and allowed to stand at room temperature, in the 
dark, for 60 min.  Absorbances were read at 750 nm using a BioTek µ-Quant microplate 
reader (BioTek Instruments, Inc. Winooski, VT). The optical density values (O.D.) were 
converted to total phenolics, and expressed as milligram gallic acid equivalents 
(GAE)/100 ml and then to mg GAE/g dry weight (DW).  Each sample was measured in 
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triplicate and GAEs were calculated from the standard curve.  Total soluble phenolic 
standard curves were prepared before each experiment using various concentrations of 
gallic acid (100, 200, 300, and 400 mg/l) in methanol. 
Major phenolics determination. Major phenolics were determined using condi-
tions described by Pastrana-Bonilla et al. (2003).  Briefly, extracted samples were filtered 
through a 0.2 μm nylon syringe filter (VWR International, West Chester, PA) and in-
jected into a Hewlett-Packard (Avondale, PA) HP 1090 HPLC (high-performance liquid 
chromatography) system with diode array and fluorescence detectors.  The mobile phases 
were, solvent A, methanol/acetic acid/water (10:2:88, v/v/v); solvent B, acetonitrile; and, 
solvent C, water.  The linear gradient used for phenolic separation was as follows: at 0 
min., 100% solvent A; at 5 min. 90% solvent A and 10% solvent B; and at 25 min., 30% 
solvent A and 70% solvent B, with 5 min. postrun with 100% solvent C.  The flow rate 
was 1 ml/min.  The Regis REXCHROM C18 ODS 4.6 x 250 mm column was used with 
a column temperature of 45 °C.  The sample injection volume was 20 µl.  All extractions 
were performed under reduced lighting to protect phenolic compounds from degradation. 
Helicobacter pylori strains and growth. Two cagA- and vacA-positive H. pylori 
strains, 26695 and D5178 (a clinical isolate), were used in this study.  Both strains were 
routinely grown on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, MI) (pH 
7.2 ± 0.2) supplemented with 7% horse serum (HS) (Sigma) at 37°C for 72 h under mi-
croaerophilic conditions (5% O2, 10% CO2, and 85% N2) in a GasPak jar (BBL Microbi-
ology Systems, Cockeysville, MD) (Jiang and Doyle, 2000).  Plate-grown bacteria was 
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subcultured in BHI/HS broth (pH 7.2) and grown overnight at 37 °C in conical flasks, 
with shaking (120 rpm), under microaerophilic conditions.   
Active phenolics determination from MGS extracts. To determine active phe-
nolics, H. pylori 26695 was grown as described, washed twice in phosphate buffered sa-
line (PBS, pH 7.4) and inoculated onto BHI-HS agar plates (ca. 5 x 10
7
 CFU/plate) using 
an Autoplate 4000 spiral plater (Spiral Biotech, Inc., Norwood, MA).  Twenty-five mi-
croliters of each extract, adjusted to 2 mg/ml total phenolics, was added to sterile cotton 
disks (6 mm in diameter) (Becton, Dickenson and Company, Franklin Lakes, NJ), placed 
onto freshly inoculated plates, and incubated under microaerophilic conditions for 72 h or 
until visible growth occurred.  Each test was performed in triplicate.  Following incuba-
tion, zones of inhibition were measured to the nearest millimeter and visually compared 
to determine any differences among MGS extract effectiveness.  After determining phe-
nolic concentrations by HPLC for each extract, single phenolics and all possible combi-
nations were tested against the same strain under identical conditions to deduce which 
phenolic(s) were most likely responsible for anti-H. pylori activity. 
In vitro analysis of active compounds in combination against H. pylori. Com-
bination effects of quercetin and resveratrol were tested using a two-dimensional check-
erboard assay (McLaren, 1997) in 96-well cluster trays (Corning Costar Corp., Cam-
bridge, MA).  Briefly, quercetin and resveratrol were suspended in DMSO, filter-
sterilized, and added to BHI/HS broth yielding final concentrations ranging from 8 to 512 
and 2 to 512 µg/ml, respectively.  H. pylori was grown as previously described and added 
to wells containing compounds or broth plus DMSO (control) for a final concentration of 
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approximately 1 x 10
7
 CFU/ml.  Plates were incubated under microaerophilic conditions, 
without shaking, for 24 h and 48 h.  At each time point, wells were sampled using a repli-
ca plater (Sigma) and aseptically transferred (ca. 2 µl/pin) to BHI/HS agar plates supple-
mented with vancomycin (100 µg/ml), polymyxin B (3.3 µg/ml), bacitracin (200 µg/ml), 
amphotericin B (50 µg/ml), and nalidixic acid (10.7 µg/ml) (Sigma, St. Louis, MO) and 
incubated microaerobically for up to 1 week.  Plates were scored by assessing the amount 
of growth on each spot.  No growth = 0; 1-5 colonies = 1; 6-10 colonies = 2, 11-15 colo-
nies = 3; 16-20 colonies = 4; > 20 colonies = 5; confluent growth = 6.  Results were then 
analyzed by calculating the fractional bactericidal concentration (FBC) and consequent 
FBC index and mean FBC index.  Synergy = mean FBC index of < 0.5; an additive effect 
= mean FBC index of 0.5-1; and antagonism = mean FBC index of > 1.  All tests were 
performed in triplicate. 
Rate-of-kill analysis of compounds against H. pylori. The bactericidal activity 
of quercetin, resveratrol, and amoxicillin were determined using a modification of the 
Miles-Misra method (McLaren, 1997).  Briefly, H. pylori 26695 and D5178 was grown 
as previously described and resuspended in BHI/HS broth to a final concentration of ca. 5 
x 10
6
 CFU/ml.  Time-course killing effects were determined at both neutral (pH 7.4±0.2) 
and acidified (pH 5.8±0.2) conditions (the latter reflecting pH conditions in the human 
gastric juxtamucosal environment) (Fahey et al., 2002).  Quercetin, resveratrol, and 
amoxicillin were tested at 0.5x, 1x, 2x, and 4x the MIC determined previously (Brown et 
al., 2010, data not shown).  After 0, 1, 3, 6 and 24 h of incubation at 37°C under static, 
microaerophilic conditions, samples were serially diluted in 0.85% saline and plated onto 
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BHI/HS supplemented with the antibiotic mixture previously described.  Untreated H. 
pylori was plated as a control.  Tests were performed in triplicate and expressed as mean 
log10 CFU/ml. 
Uptake of 1-N-phenylnapthylamine (NPN) by H. pylori. NPN uptake assays 
were performed as described by Bina et al. (2000) with some modifications.  Briefly, 
overnight liquid cultures of H. pylori 26695 were harvested by centrifugation (3,500 x g, 
10 min), washed twice in 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) buffer (pH 7.4) containing 10 µM MgCl2, and resuspended to an O.D. at 600 
nm of 0.5 in 5 mM HEPES-5 mM glucose.  Cell suspensions were aliquoted and used 
immediately in the uptake assays.  NPN fluorescence was measured using black 96-well 
plates (Greiner Bio-One Inc., Monroe, NC).  Aliquots (100 µl) of the cell suspension 
were added to each well containing 50 µl of quercetin (40 µM, final concentration), res-
veratrol (40 µM), EDTA (1 and 0.5 mM) or HEPES buffer (with and without MgCl2) as a 
control.  Fluorescence measurements were performed using a SPECTRAmax GEMINI 
microplate spectrofluorometer (Molecular Devices, Inc., Sunnyvale, CA) with an excita-
tion wavelength of 350 nm and an emission wavelength of 420 nm.  Following the addi-
tion of NPN (10 µM final concentration), measurements were taken following 30 min 
incubation at 37 ° C, with shaking before each read.  All NPN assays were performed in 
triplicate.  
Uptake of quercetin and resveratrol by H. pylori. To determine quercetin up-
take, H. pylori 26695 was grown in BHI/HS broth overnight to mid-logarithmic phase 
(15-16 h) determined by a previous growth curve (data not shown).  Cells were pelleted 
75 
 
by centrifugation (3,500 x g, 10 min), washed once in sterile PBS (pH 7.4±0.2), and re-
suspended in BHI broth (without HS) to a final concentration of ca. 1 x 10
8
 CFU/ml.  
Heat-inactivated controls were prepared by boiling cells (100 °C) for 15 min.  After cool-
ing to room temperature, quercetin was added to live and heat-inactivated cell suspen-
sions at a final concentration of 256 µg/ml.  In addition, quercetin (in DMSO) was added 
to broth as a cell-free control.  Cells were incubated microaerobically at 37 °C for 0, 1, 2, 
and 3 h.  At each time point, H. pylori counts were determined by serially diluting sam-
ples in 0.85% saline, plating onto BHI/HS, and incubating microaerobically for up to 1 
week.  Additional samples were also collected at each time point and analyzed by HPLC 
under the described conditions.  For this, 5 ml aliquots were collected and centrifuged at 
12,000 x g for 10 min at 4°C.  Supernatants were removed and stored at -20 °C until 
analysis.  Bacterial pellets were washed twice in sterile PBS (pH 7.4) and resuspended to 
1 ml in the same buffer.  Cells were then subjected to ultrasound for 8 min at 30 sec in-
tervals with a 1 min cooling period between pulses.  All samples were kept on ice during 
cell lysis.  Sonicates from each collection time were plated onto selective media de-
scribed previously to verify total cell lysis.  Cell material was pelleted by centrifugation 
at 4,000 x g for 10 min at 4 °C and the supernatant was collected for immediate HPLC 
analysis using the same conditions described above.  
Salt aggregation assay. Salt aggregation assays were done to determine the H. 
pylori cell surface hydrophobicity in the presence of quercetin, resveratrol, or MGS.  Pro-
cedures were performed as described by Annuk et al. (1999) with some modifications.  
Briefly, overnight liquid cultures of H. pylori 26695 were harvested by centrifugation 
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(3,500 x g, 10 min) and resuspended in 0.01 M NaPO4 (pH 7.4) with 0.15 M NaCl and 
adjusted to an O.D. at 600 nm of 1.0.  Fifty-microliters of ammonium sulfate diluted in 
0.02 M NaPO4 buffer (0.05 M-3.0 M) was mixed with an equal volume of H. pylori cell 
suspension (control) or suspensions treated with quercetin, resveratrol, or MGS extract 
for 15 min at room temperature and added to U-shaped microwells (Nalge Nunc Interna-
tional, Rochester, NY).  Plates were incubated for 3 h at room temperature under micro-
aerophilic conditions and visually compared to determine aggregation.  Salt aggregation 
was defined as positive if bacterial aggregation was clearly visible and negative if no ag-
gregation was observed.  The salt aggregation titer was defined as the lowest concentra-
tion of ammonium sulfate at which bacteria still showed cell aggregation.  All tests were 
performed in duplicate. 
Phase-contrast microscopy of H. pylori. For phase-contrast microscopy, scoring 
criteria described by O‘Gara et al. (2000) were used with some exceptions.  Briefly, H. 
pylori 26695 was grown in BHI/HS broth overnight as described, washed once in 0.85% 
saline, and resuspended in BHI/HS broth to ca. 1 x 10
8
 CFU/ml.  Cell suspensions were 
treated with quercetin (256 µg/ml) or DMSO (control) and incubated at 37 °C under mi-
croaerophilic conditions.  At 0, 1, 3, 6 and 24 h, cells were collected and observed using a 
Leica DM E microscope with phase-contrast settings (Leica Microsystems GmbH, Wet-
zlar, Germany) to compare time-course bactericidal data with real-time phenotypic 
changes.  For scoring, the average of at least five fields of view per time point was used.  
All experiments were performed in duplicate.   
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Statistical Analysis. One and two-way ANOVA tests were used to determine dif-
ferences between data.  All values were considered statistically significant at P < 0.05 
using SAS 9.1 software (SAS Institute Inc., Cary, NC). 
Results 
Major and active phenolics determination from MGS extracts. Total phenol-
ics were determined from four MGS samples following extraction and ranged from 67.9 
to 109.8 mg GAE/g DW of starting material.  Standardized extracts (2 mg total phenol-
ics/ml) were then evaluated for antimicrobial activity (Figure 3.1) and subjected to 
HPLC.  This was done to reveal any measurable difference in major phenolic profiles and 
determine selected phenolic concentrations (ellagic acid, myricetin, quercetin, trans-
resveratrol, gallic acid).  These compounds were chosen because they constitute much of 
the total phenolics present in MGS as determined previously, have been chemically cha-
racterized, are commercially available, and have previously been reported to possess an-
timicrobial properties against a wide variety of organisms, including H. pylori.   
Major phenolics were identified by their retention times and characteristic spectra 
from HPLC chromatograms.  Quantification was made by comparing peak areas to those 
obtained from phenolic standards at known concentrations.  Selected compounds were 
also verified by UV-Vis spectrometry.  Table 3.1 shows the major phenolics identified 
and quantified in selected muscadine cultivars. 
Following chemical analysis, pure phenolics at equivalent concentrations to those 
in Table 3.1 were tested alone and in combinations against H. pylori 26695 by disk-
diffusion in order to elucidate the most active phenolic(s).  Inhibition zones were meas-
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ured and compared to those using MGS extracts to determine which compound(s) was 
most effective against H. pylori growth and if any additive/synergistic effect was evident 
between compounds (Table 3.2). 
Based on disk diffusion results, MGS extracts were the most effective against H. 
pylori growth; suggesting possible synergistic action among compounds present in MGS 
preparations.  To further support this hypothesis, all major phenolic compounds were 
then combined at concentrations equivalent to those determined previously by chemical 
analyses (Table 3.2).  However, the same result (i.e. inhibition diameter) could not be ob-
tained; suggesting the presence of additional unidentified antimicrobial components in 
MGS not determined in this study.  Although we were unable to determine the definitive 
compound(s) responsible for activity using MGS, quercetin repeatedly showed the high-
est anti-H. pylori activity with large zones of inhibition, clearly defined edges, and no 
observable tailing.  When combined with resveratrol, quercetin showed a marked in-
crease in activity.  Therefore, quercetin and resveratrol were selected for further evalua-
tion. 
Bactericidal activity of quercetin and resveratrol alone and in combination. 
Having established the bacteriostatic activity of quercetin previously (MIC, 32-64 µg/ml) 
and resveratrol (MIC, 16-32 µg/ml) against multiple H. pylori strains (Brown et al., 2009; 
Brown et al., 2010), we next evaluated the compounds‘ bactericidal potency by using a 
time-to-kill assay with the reference strain (26695) and a clinical isolate (D5178).  All 
experiments were run in parallel at pH 7.4 (neutral) and 5.8 (acidic) since most H. pylori 
colonize the mucous layer and gastric pits of the antrum where the pH is believed to be 
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~5.5 (Fahey et al., 2002).  Bactericidal activity was defined as a reduction in plate counts 
of ≥1,000 CFU/ml (Fahey et al., 2002).  In addition to quercetin and resveratrol, amox-
icillin was chosen as a reference drug because of its low MIC (MIC, 0.25 µg/ml) and 
since resistance has not been extensively reported in H. pylori.  In time course studies 
with quercetin and resveratrol (Figure 2), similar dose-dependent patterns upon H. pylori 
26695 and D5178 were observed at all concentrations and the MICs and MBCs corres-
ponded appropriately with those obtained in additional 24-h MIC and MBC experiments.  
Lag phages of 1-3 h were observed.  Anti-H. pylori activity was greater (2-fold-lower 
MIC and MBC) for resveratrol than quercetin.  There was no effect of changes in pH 
over the range examined with either strain or any of the compound concentrations tested.  
At all of the subinhibitory concentrations (1X and 0.5X the MIC) of quercetin and amox-
icillin tested against strains 26695 and D5178, significant reductions (P > 0.05) in viable 
cell counts were not observed at any time during the assay.  Interestingly, 2X concentra-
tions of resveratrol did not result in significant reductions (P > 0.05) over the 24 h treat-
ment period (similar to lower doses); suggesting that a concentration threshold must be 
achieved before resveratrol activity is bactericidal against H. pylori. 
Since both quercetin and resveratrol showed a concentration- and time-dependent 
effect on H. pylori (P < 0.05) and preliminary tests suggested that quercetin and resvera-
trol may act synergistically or additively against H. pylori growth, both compounds were 
tested using a checkerboard assay for 24 and 48 h with results shown in Figure 3.3. 
From checkerboard assays, quercetin and resveratrol together showed synergistic 
activity against H. pylori 26695 with an FBC index of ≤ 0.5 at both 24 and 48 h.  Minim-
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al bactericidal concentrations of quercetin and resveratrol required to completely kill H. 
pylori were lower with extended treatment time.  The lowest combined concentrations of 
quercetin and resveratrol required to completely kill H. pylori was 16 µg and 128 µg/ml 
(24 h) and 8 µg and 64 µg/ml (48 h), respectively. 
Effect of quercetin and resveratrol on H. pylori membrane permeability. Fig-
ure 3.4 shows the results of NPN uptake with quercetin, resveratrol, or EDTA (a permea-
bilizer acting by chelation) with or without MgCl2.  EDTA weakened the outer membrane 
of H. pylori as indicated by strong increases in NPN uptake.  Neither quercetin nor resve-
ratrol enhanced NPN uptake suggesting that their effects on H. pylori are likely not asso-
ciated with reducing outer membrane integrity.  The addition of MgCl2 had no significant 
(P > 0.05) impact on fluorescence levels with any treatment other than EDTA. 
Quercetin uptake by H. pylori. Quercetin and resveratrol did not affect H. pylori 
outer membrane integrity as revealed by NPN assays.  Therefore, we next set out to de-
termine the degree of quercetin uptake by H. pylori as reported in other cell types.  To do 
this, H. pylori 26695 was treated with quercetin for 1, 2, and 3 h under conditions de-
scribed previously.  HPLC was then used to measure quercetin uptake in live, metaboli-
cally active H. pylori cells while measuring overall flavonoid losses in culture superna-
tant, inactive cell biomass (i.e. cell membranes/protein) and cell-free controls (to account 
for possible oxidation losses) to confirm active drug uptake and validate our approach.  
 Quercetin levels in live H. pylori cells were highest following 1 h incubation with 
20.2 µg/ml detected in cell lysates.  At 2 and 3 h, quercetin levels decreased to 14.7 and 
11.5 µg/ml, respectively, while at the same time reducing H. pylori counts approximately 
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0.2 logs (Figure 3.5).  Of the initial quercetin amount added (256 µg/ml), inactive cell 
biomass accounted for 3.5% of quercetin losses whereas culture supernatants and cell-
free controls accounted for losses of 24.1 and 18.6%, respectively (Figure 3.6). 
Morphological and physiological changes in H. pylori following quercetin 
treatment. Phase-contrast microscopy revealed noticeable changes in both the behavior 
and morphology of H. pylori cells treated with quercetin (Table 3.3 and Figure 3.7).  
Within 1 h of exposure to quercetin (256 µg/ml), vigorous motility declined and 10 to 
15% of cells, previously spiral rod-shaped, appeared as coccoidal forms.  In addition, cell 
clumping was clearly visible and increased with time, especially following 3 h treatment.  
Within 6 h, viability dropped approximately 2 logs with the number of spiral rods below 
10%.  At 24 h, all cells were coccoidal and non-motile with large amounts of cellular de-
bris clearly visible. 
Cell surface hydrophobicity following quercetin, resveratrol, or MGS treat-
ment. To determine H. pylori cell surface hydrophobicity (CSH), the salt aggregation 
(SA) assay was performed.  H. pylori 26695 in phosphate buffer did not aggregate at or 
below 1.5 mM ammonium sulfate during incubation.  Quercetin and resveratrol (alone 
and in combination) slightly enhanced cell aggregation while MGS extract showed the 
greatest effect with cell aggregation observed at the lowest salt concentration tested (Ta-
ble 3.4). 
Discussion 
Polyphenols possess significant anti-H. pylori activity as shown previously 
(Brown et al., 2009; Brown et al., 2010).  However, the primary bioactive component(s) 
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in MGS extracts against H. pylori has yet to be definitively identified but is believed to 
be a major phenolic based on earlier reports and established chemical profiles (ellagic 
acid > myricetin > quercetin > resveratrol > gallic acid).  Therefore, in this study, further 
work was done to elucidate the most active chemical constituent(s) in MGS responsible 
for anti-H. pylori activity and explore some of the proposed interactions between these 
compounds and H. pylori.  Following extraction and determination of phenolic concen-
trations among four muscadine grape varieties, and subsequent in vitro screening, it was 
found that quercetin, while in association with resveratrol, yielded the greatest anti-H. 
pylori activity. 
Quercetin (3, 3′, 4′, 5, 6-pentahydroxyflavone) is a naturally-occurring dietary 
flavonol found in MGS and one of the most widely studied phenolics known.  Flavonols 
exhibit numerous biological and pharmacological effects, including antioxidant, 
chelation, anti-carcinogenic, cardioprotective, antibacterial, and secretory properties 
(Gross et al., 1996, Middleton et al., 2000).  Resveratrol (3, 5, 4′-trihydroxystilbene) is a 
naturally occurring stilbene found in grapes and red wine and also exhibits many 
physiological effects associated with health benefits. 
 When evaluating antimicrobial agents against H. pylori, several important factors 
must be taken into consideration given its basic physiology and environmental niche.  
When assessing the suitability of an agent for the reduction/eradication of H. pylori, 
speed of kill (i.e. bactericidal activity) is critical as most agents have a short lifespan in 
the stomach (Millar and Pike, 1992).  In addition, acid stability and emergence of resis-
tant variants must also be evaluated.  Following time-course viability studies, quercetin 
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and resveratrol both demonstrated cidal modes of action against H. pylori regardless of 
pH conditions.  Although MBCs were high compared to amoxicillin, neither quercetin 
nor resveratrol have any reportable toxicity and are generally regarded as safe at high le-
vels.  To analyze drug interactions, a checkerboard assay was used and revealed a syner-
gistic mode of action against H. pylori.  MBCs of both quercetin and resveratrol were 
significantly lower when used in combination suggesting that these compounds would be 
most effective when taken together.  Finally, since quercetin and resveratrol are believed 
to affect unique cellular targets simultaneously, the possibility of drug resistance may be 
reduced. 
Polyphenols have been reported to interact with various biological components 
such as cell membrane proteins and DNA (Kaldas et al., 2005; Walle et al., 2003).  Be-
cause of its hydrophobic nature, the flavonoid quercetin may also interact with sites such 
as the lipid bilayer of cell membranes (LoCascio et al., 2006) disrupting normal proton 
pump function (i.e. electron transport and H
+
-ATPase) resulting in loss of proton motive 
force.  In addition, polyphenols may interact with cellular (e.g. transmembrane) and/or 
secreted proteins (55- to 80-kDa) (Kaldas et al., 2005); altering their conforma-
tion/activity, destabilize membranes causing cells to become ‗leaky‘, or simply accumu-
late in the plasma membrane resulting in loss of function and cell death.  We previously 
reported that MGS extracts and constitutive polyphenols may also affect H. pylori at-
tachment while reducing VacA-induced vacuolation in AGS (CRL-1739) cells (Brown et 
al., 2009).  Other studies have also shown the effectiveness of polyphenols against H. py-
lori growth, toxicity, urease production, and adherence (Yahiro et al., 2005; Lin et al., 
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2005; Burger et al., 2000; Pastene et al., 2011); thereby supporting results from our earli-
er studies and emphasizing that these compounds, although diverse in origin, may share 
some common structural feature(s) which allow them to exert similar activities against H. 
pylori.   
In order to determine the some of the possible interactions between quercetin and 
H. pylori, two different approaches were used.  To determine whether quercetin or resve-
ratrol affect H. pylori via disruption of its outer membrane (OM), 1-N-
phenylnaphthylamine (NPN) uptake in H. pylori 26695 was measured following expo-
sure to these compounds or EDTA in the presence or absence of MgCl2.  NPN is a small 
hydrophobic fluorescent probe used to determine the hydrophobic and self-promoted up-
take pathways across the outer membranes of gram-negative bacteria (Bina et al., 2000).  
Fluorescence results from this probe associating with a glycerophospholipid environment 
such as the lipid bilayers of the OM interior.  Therefore, increased fluorescence values 
indicate weakening of the biological membrane.  NPN is normally excluded from the OM 
by the outer monolayer comprised of the polyanion lipopolysaccharide, stabilized by di-
valent cross bridging and fluoresces only weakly in the extracellular aqueous environ-
ment (Bina et al., 2000).  Although many bacteria require destabilization of the OM be-
fore uptake of hydrophobic antibiotics, usually through a destabilizing polycation such as 
polymyxin B, H. pylori has been reported to demonstrate relatively high intrinsic uptake 
of NPN compared to other bacterial types. 
Neither quercetin nor resveratrol increased NPN fluorescence levels in H. pylori 
compared to no-treatment controls, regardless of time or concentration; suggesting a lack 
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of damage to the OM.  However, the possibility of active NPN efflux could not be com-
pletely ruled out.  Observations of H. pylori by phase-contrast microscopy revealed that 
cells in the presence of quercetin, with glucose (5 mM), appeared to become deenergized 
over time via reduced motility possibly suggesting the absence of active NPN efflux.  
This may also suggest that the plasma membrane is affected; however, this was not de-
termined. 
Since neither quercetin nor resveratrol affected OM integrity, we next chose to 
examine quercetin uptake by H. pylori.  Quercetin has been reported to rapidly accumu-
late in the cytosol and mitochondria of eukaryotes (Fiorani et al., 2005; Walgren et al., 
2000); however, its transport into bacteria has yet to be fully established.  Quercetin was 
previously found to enter both aerobic and anaerobic, gram-positive bacteria and Saccha-
romyces cerevisiae while in resting states (Braune et al., 2001; Schoefer et al., 2003; Lo-
Cassio et al., 2006).  To date, no reports exist regarding quercetin uptake by H. pylori.  
However, given its relatively high sensitivity to hydrophobic antimicrobials, including 
numerous plant-derived compounds (many with low water solubility) (and NPN as dis-
cussed above), we believe that quercetin may enter the cell via non-specific OM porins 
such as HopE, forming large channels compared to less sensitive gram-negatives.  This 
may permit passage into the periplasm and subsequent accumulation of quercetin in the 
cytosol via passive or active transport systems. 
To determine quercetin uptake, H. pylori cells and culture supernatants were 
measured to determine intracellular compound accumulation.  Because quercetin may 
oxidize and degrade during extended incubation, cell-free negative controls were in-
86 
 
cluded for each trial.  In addition, because quercetin may passively bind to various com-
ponents in the cytoplasmic and/or OM, basal levels of quercetin absorption onto metabol-
ically inactive cell biomass were determined using heat-inactivated H. pylori controls.  
Therefore, any difference between quercetin detected in extracts of live cells and heat-
inactivated cells, cell-free controls, or culture supernatants would indicate active uptake. 
Because bacterial numbers declined during treatment, accumulation rates and drug efflux 
could not be determined.  However, if quercetin was pumped out of the cell, levels should 
have increased over time in cell supernatants; minus oxidation and losses due to washing 
and/or extraction (lysis efficiency was 100% since no detectable growth following soni-
cation).  Differences in quercetin levels gained or lost may be attributed to its intracellu-
lar degradation by metabolically active H. pylori.  This may further explain why querce-
tin levels decreased over time in cell pellets but were not detected in corresponding su-
pernatants; however, no metabolites were revealed by our chromatographic method. 
Following treatment, relatively high levels of quercetin were detected in live H. 
pylori extracts.  Therefore, four possibilities were proposed.  Quercetin may have 1) in-
tercalated in the hydrophobic region of the cell membrane lipid bilayer, 2) passively dif-
fused through the cell membrane into the cell cytosol, 3) interacted with cell membrane 
proteins, or 4) been actively imported into the cytosol.  Also, it should be noted that a 
combination of these factors may have contributed to quercetin detection.  However, if 
quercetin did passively intercalate within the cell membrane or associate with cell mem-
brane proteins, similar amounts should have been detected in heat-inactivated controls as 
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live, metabolically active cells.  Because quercetin levels were low in controls compared 
to live cell extracts, we believe that quercetin must have entered the cytosol.   
 By tracking H. pylori cells exposed to high concentrations of quercetin via phase 
microscopy, there appeared to be an increase in coccoidal cell morphology and reduc-
tions in spiral and rod forms over time.  This result corresponded well with overall re-
duced cell viability and cell motility, possibly indicating a loss of proton motive force 
and/or active drug efflux.  Increases in cellular debris following 24 h exposure indicates 
progressive cellular destruction, suggesting that quercetin and other polyphenols may in-
terfere with the bacterial cell envelope, causing cell lysis, or with cell metabolism, trig-
gering autolysis.  Based on uptake assays (NPN and HPLC), the latter is more likely; 
however, this has yet to be fully determined. 
Pathogenic bacteria commonly attach to target tissues via species-specific adhe-
sion receptor mechanisms.  However, microbial cell surface hydrophobicity (CSH) is also 
associated with binding to the specific cell and tissue receptors of the host mucosal sur-
face.  Given the results from our initial study (Brown et al., 2009) and phase-contrast mi-
croscopy, H. pylori cells appeared to aggregate following treatment with quercetin.  H. 
pylori does not possess high CSH as shown by the SA assay.  However, some strains 
have been found to have high CSH as reported following hydrophobic interaction chro-
matography (Smith et al., 1990).  For many bacterial infections, adhesive strains often 
possess high CSH values as determined by SA and other methods.  It has been proposed 
that the relatively low CSH of H. pylori may allow the organism to attach and then pene-
trate the gastric mucus layer.  Following treatment with quercetin, resveratrol, and MGS 
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extract, only moderate increases in CSH were measured for both quercetin and resvera-
trol.  However, MGS extract treatment greatly increased CSH (corresponding cell aggre-
gation at low salt concentration) and may suggest other polyphenols may also interfere 
with initial attachment of H. pylori. 
In this study, we examined the anti-H. pylori properties of different muscadine 
grape cultivars and determined that the major phenolics quercetin and resveratrol located 
in the skin have the strongest anti-H. pylori activity in vitro, especially when used in 
combination, and are independent of pH.  Neither quercetin nor resveratrol were found to 
affect H. pylori OM integrity or significantly alter CSH as previously hypothesized.  
However, treatment with MGS did increase NPN uptake; indicating OM destabilization, 
and increase CSH possibly by additional unknown components not revealed in this study.  
Furthermore, quercetin was found to decrease H. pylori motility while being transported 
into the cell cytosol suggesting its primary anti-H. pylori activity may be linked to its in-
teraction with intracellular components; however this has yet to be fully determined.  Our 
results indicate that MGS extracts and constitutive phenolics quercetin and resveratrol 
exert strong anti-H. pylori activity and may have the potential to be incorporated into an 
effective, diet-based approach for prevention and/or treatment of H. pylori infection. 
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Figure Legend 
 
FIGURE 3.1.  Photograph of H. pylori 26695 plated on BHI/HS following treatment 
with standardized MGS (2 mg/ml total phenolics) extracts by the disk-diffusion method. 
 
FIGURE 3.2. Time-course bactericidal activity of quercetin (A), resveratrol (B) and 
amoxicillin (C) on H. pylori 26695 after exposure to 0.5x, 1x, 2x, and 4x the MIC at pH 
7.4 (a) and pH 5.8 (b).  MICs were 32 and 16 µg/ml for quercetin and resveratrol, respec-
tively. 
 
FIGURE 3.3.  Synergistic activities of quercetin and resveratrol against H. pylori 26695 
at 24 (A) and 48 (B) h.  FBC index ≤ 0.5. 
 
FIGURE 3.4. Uptake of NPN by H. pylori 26695 in the presence of EDTA, MGS, quer-
cetin (40 µM, 13.3 µg/ml) and resveratrol (40 µM, 9.1 µg/ml) with or without MgCl2.  
MGS, muscadine grape skin extract (~1 mg total phenolics/ml); RFU, relative fluores-
cence units. 
 
FIGURE 3.5. Uptake of quercetin into live H. pylori 26695 cells over time. 
 
FIGURE 3.6. Quercetin distribution following 3 h incubation of H. pylori 26695 with 
256 µg/ml of quercetin. 
 
FIGURE 3.7. Phase-contrast microscopy images of H. pylori 26695 during exposure to 
quercetin (256 µg/ml) for 1 (A), 2 (B), and 3 (C) hours.  Magnification, x1000. 
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TABLE 3.1.  Major phenolics in muscadine grape skin (MGS) extracts as analyzed by 
HPLC. 
 
 Major phenolic (µg/ml extract)a 
Cultivar ellagic acid myricetin quercetin resveratrol gallic acid 
Carlos 728.7 230.0 96.0 24.4 119.8 
Woodruff 764.1 70.6 125.8 69.9 102.3 
Noble 411.0 133.0 21.4 83.3 125.7 
Cowart 739.8 113.3 210.4 181.1 34.5 
 
a
Approximate concentration calculation based on 200 µg/ml standards.  All MGS samples contained ~2 
mg/ml of total soluble phenolics. 
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TABLE 3.2. H. pylori 26695 inhibition by major phenolic combinations by disk-
diffusion. 
 
phenolic combination 
Total phenolics 
(µg/ml) 
Zone diameter 
(mm)a 
ellagic acid 739.8 9 
ellagic acid, myricetin 853.1 9 
ellagic acid, quercetin 950.2 11 
ellagic acid, resveratrol 920.9 10 
ellagic acid, gallic acid 774.3 9 
myricetin 113.3 10 
myricetin, quercetin 323.7 13 
myricetin, resveratrol 294.4 12 
myricetin, gallic acid 147.8 11 
quercetin 210.4 13 
quercetin, resveratrol 391.5 16 
quercetin, gallic acid 244.9 13 
resveratrol 181.1 12 
resveratrol, gallic acid 215.6 11 
gallic acid 34.5 8 
ellagic acid, myricetin, quercetin, resveratrol, gallic acid 1279.1 17 
MGS extract 2000.0 20 
DMSO  0 0 
 
a
Average of three independent experiments; MGS, Cowart muscadine grape skin; DMSO, solvent control. 
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TABLE 3.3. Visible effects of quercetin (256 µg/ml) on H. pylori 26695 by phase-
contrast microscopy. 
Time 
(h) 
No. of 
spiral rodsa 
Clumpingb Cocci (%) Motilityc 
Viable 
count log10 
0 >25 0 0 +++ 7.8 
1 15-25 1 10-15 ++ 7.5 
3 1-10 2 25-30 + 7.2 
6 <10 3 50-75 - 5.4 
   24 0 3 100 - 3.5 
 
a
Number of rods observed per field of view. 
b
Clumping rated on a scale of 1 to 4 as follows: 1, motile clumps containing ≤10 cells; 2, nonmotile clumps 
containing 10 to 15 cells; 3, nonmotile clumps containing 15 to 20 cells; 4, nonmotile clumps containing 
≥20 cells. 
c
 -, no movement; +, slow; ++, moderate; +++ fast movement. 
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TABLE 3.4. Salt aggregation of H. pylori 26695 treatment with quercetin, resveratrol, or 
MGS extract. 
 
Treatment 
Ammonium sulfate concentration (M) 
3.0 1.5 1.0 0.5 0.25 0.1 0.05 Controla 
H. pylori + - - - - - - - 
Quercetin + + + - - - - - 
Resveratrol + + - - - - - - 
Synergyb + + + - - - - - 
MGSc + + + + + + + - 
 
a 
Control, H. pylori treated with DMSO in phosphate buffer without (NH4)2SO4. 
b
 Synergy, quercetin (256 µg/ml) and resveratrol (128 µg/ml). 
c
 MGS, muscadine grape skin (2 mg GAE phenolics/ml). 
d
 +, cell aggregation 
e
 -, no cell aggregation 
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FIGURE 3.3. 
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FIGURE 3.4. 
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FIGURE 3.5. 
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FIGURE 3.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
FIGURE 3.7. 
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CHAPTER FOUR 
GENE EXPRESSION OF HELICOBACTER PYLORI TREATED WITH  
MUSCADINE GRAPE SKIN EXTRACT OR ITS POLYPHENOLIC 
CONSTITUENTS QUERCETIN AND RESVERATROL 
Abstract 
The effects of sub-inhibitory concentrations of muscadine grape skin extract 
(MGSE) and constitutive polyphenols quercetin and resveratrol on Helicobacter pylori 
transcripts were determined by microarray analyses.   Following 15 min exposure, 63, 39, 
and 29 genes were found to be differentially expressed in MGSE-, quercetin- and resvera-
trol-treated cells, respectively, with only one overlapping gene detected between resvera-
trol and quercetin treatments.  Interestingly, ATP synthase was induced upon quercetin 
and MGSE exposure while shikimate 5-dehydrogenase was induced in quercetin-treated 
cells.  In addition to highlighting possible primary targets of quercetin and resveratrol, 
cagA and ureA genes were significantly repressed as confirmed by quantitative reverse 
transcriptase PCR (qRT-PCR).  This may further support the potential use of plant-based 
polyphenolic compounds for H. pylori prevention and/or treatment.  This study also de-
monstrates that with low inhibitor concentration and short incubation periods, relatively 
few genes show a clear change in expression following antimicrobial treatment and may 
be optimal for the analysis of primary response mechanisms in H. pylori exposed to un-
characterized natural compounds.  Results from this study may be useful in determining 
quercetin or resveratrol‘s primary mode(s) of action against H. pylori in the future; how-
ever, additional studies are necessary to confirm these predicted targets.   
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Introduction 
Helicobacter pylori is a microaerophilic, gram-negative bacterium and among the 
most persistent of all human pathogens.  Its presence in the gastric environment is corre-
lated with diseases such as gastritis, peptic ulcers, mucosa-associated lymphoid tissue 
lymphoma, and gastric carcinoma (Cover and Blaser, 1995; Rothenbacher and Brenner, 
2003).  The continued emergence of antibiotic-resistant strains emphasizes the need to 
identify new therapeutic targets for the treatment and/or prevention of H. pylori infection.  
It has been shown that people consuming diets rich in fruits and vegetables have a lower 
incidence of infection and severe gastric malignancies and that this may be due to consti-
tutive bioactive compounds acting against H. pylori (Testerman et al., 2001).  
We believe that alternative, diet-based strategies may have a significant impact on 
attenuating this bacterium when used alone or in combination with current antibiotic re-
gimes; however, natural compounds used should be better studied to understand their full 
therapeutic potential.  In addition, cellular targets should be elucidated prior to use to de-
termine possible interactions they may elicit on their conventional antimicrobial counter-
parts.  Muscadine grapes, because of their high levels of bioactive compounds (e.g. ellag-
ic acid, myricetin, quercetin, resveratrol, etc.) and unique chemical makeup, are believed 
to be a proper candidate for study since these fruits have already been shown to exert an-
ti-H. pylori activity both in vitro and in vivo with effects possibly related to bacterial at-
tachment or virulence factors (Brown et al., 2009; Brown et al., 2010). 
Previous studies have reported the anti-H. pylori activity of quercetin and resvera-
trol as well as numerous plant-based extracts (Gonzalez-Segovia et al., 2008; Mahady et 
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al., 2003).  Although it has been proposed that polyphenols may act against H. pylori 
(and other bacteria) via their interactions with cell membrane proteins and DNA (Tsu-
chiya et al., 1996; Cowen, 1999; Chan, 2002), these targets have yet to be fully estab-
lished.  One exception is that quercetin‘s antimicrobial activity can be attributed in part to 
its inhibition of DNA gyrase and ATP synthase activity in Escherichia coli (Plaper et al., 
2003; Dadi et al., 2009).  Myricetin has also been reported as having activity against E. 
coli; inhibiting helicase but not primase (Griep et al., 2007); however, these interactions 
have not been determined in H. pylori.  In addition, no report exists on resveratrol‘s poss-
ible antimicrobial mode of action.   
Although the above studies used membrane preparations and purified protein, 
they do support that different polyphenols are able to interact with multiple targets—
contributing to their overall antimicrobial activity.  However, these effects have yet to be 
determined using intact, viable cells or with H. pylori for that matter.  Furthermore, no 
studies to date have examined H. pylori gene expression changes following treatment 
with any natural compounds.  Although DNA microarrays have been used in studying 
antibiotic-induced gene expression in some bacteria, this technology has yet to be used on 
H. pylori. 
Therefore, the objective of this study was to use DNA microarrays to determine 
the patterns of relative transcript amounts in cells exposed to sublethal concentrations of 
two well-known but incompletely characterized polyphenols, quercetin and resveratrol, 
as well as muscadine grape skin extract (MGSE) in an attempt to determine their possible 
mechanism(s) of action against H. pylori 26695. 
109 
 
Materials and Methods 
Strain and growth conditions.  H. pylori strain 26695 was streaked from frozen 
stock onto Brain Heart Infusion (BHI) agar supplemented with 7% (vol./vol.) horse se-
rum (HS) and grown at 37 °C for 72 h in a GasPak jar (BBL Microbiology Systems, 
Cockeysville, MD) under microaerophilic conditions (5% O2, 10% CO2, 85% N2).  Liq-
uid cultures were grown in BHI broth containing 7% HS in 100 ml conical flasks at 37 
°C, with shaking (120 rpm), under microaerophilic conditions. 
Experimental design.  Plate-grown H. pylori was harvested and inoculated into 
BHI broth with HS, in duplicate, to an optical density at 600 nm (O.D.600) of 0.05 and 
incubated under microaerophilic conditions, with shaking, at 37°C for 15-16 h to reach 
exponential, mid-logarithmic growth as determined by established growth curves (data 
not shown).  Following incubation, cells were pelleted by centrifugation (3,500 x g, 5 
min), washed once in sterile phosphate buffered saline (PBS, pH 7.4±0.2), and resus-
pended to an O.D.600 of 0.5 in BHI/HS broth.  Two-milliliter aliquots were then distri-
buted to sterile 5 ml test tubes containing sub-lethal concentrations of MGS extract, quer-
cetin, or resveratrol in dimethyl sulfoxide (DMSO) at final concentrations of 0.1 mg total 
phenolics/ml, 32 µg/ml, and 16 µg/ml(pH 6.9 to 7.3), respectively.  Test compound con-
centrations and treatment times were determined previously (unpublished data).  Cells 
with DMSO (1%) served as negative controls.  At 15 min, samples were collected for 
RNA extraction and plated onto BHI-HS to verify bacterial survival and concentration. 
RNA isolation.  Following treatment, 1 ml aliquots of H. pylori cells were pel-
leted at 12,000 x g for 30 sec and immediately resuspended in RNAlater solution (Ap-
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plied Biosystems, Austin, TX).  Total RNA was extracted and purified using a RiboPure-
Bacteria Kit (Applied Biosystems, Austin, TX) as described by the manufacturer and 
treated with supplied DNase to remove contaminating genomic DNA.  Following purifi-
cation, RNA was precipitated overnight at -80°C with 1/10 volumes of sodium acetate (3 
M, pH 5.2) (Ambion) and 2.5 volumes of molecular grade ethanol (Sigma).  Following 
precipitation and immediately before use, RNA was recovered by centrifugation at 
16,000 x g for 15 min at 4°C, washed twice with 70% ethanol, and resuspended in TE 
buffer (Ambion).  RNA concentration and purity/integrity was verified using standard 
spectrophotometric methods (NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA) 
and an Agilent 2100 Bioanalyzer (Santa Clara, CA).  RNA was stored at -80°C until use. 
cDNA synthesis.  cDNA probes for microarray experiments were prepared as de-
scribed.  Briefly, 2 µg of total RNA was incubated at 42 °C for 18 h in a reaction mixture 
containing 6 µg of random hexamers (Invitrogen, Carlsbad, CA); 0.1 M DL-
dithiothreitol; an amino-allyl-deoxynucleoside triphosphate mixture containing 25 mM 
(each) dATP, dCTP, and dGTP, 15 mM dTTP, and 10 mM amino-allyl-dUTP (Sigma); 
5x first strand reaction buffer (Invitrogen); and 400 units of SuperScript III reverse tran-
scriptase (Invitrogen).  Following incubation, RNA template was hydrolyzed by incubat-
ing the reaction mixture at 95 °C for 5 min, snap cooling for 30 sec, adding 1 M NaOH 
(0.3 M final concentration) and incubating at 65 °C for 15 min.  Solutions were neutra-
lized with 1 M HCl (50:50, v/v).  One-tenth volume (relative to the neutralized solution) 
of 3 M sodium acetate (pH 5.2) was added and the mixture was brought to 100 µl with 
nuclease-free H2O.  Unincorporated amino-allyl-dUTP was removed using MinElute 
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PCR purification columns (Qiagen, Valencia, CA) with some modifications.  Briefly, kit-
supplied wash buffer was replaced with 75% EtOH and cDNA probes were eluted with 
phosphate buffer (4 mM KPO4, pH 8.5, in nuclease-free water), dried under vacuum at 37 
°C using a SpeedVac (Savant), and resuspended in 0.1 M sodium carbonate buffer (pH 
9.3 ± 0.1).  To couple the amino-allyl cDNA with fluorescent labels, equivalent volumes 
of normal human serum-Cy3 or normal human serum-Cy5 (Amersham Biosciences, Pis-
cataway, NJ) (in DMSO) was added to resuspended cDNA and incubated at room tem-
perature, in the dark, for 2.5 h.  Following incubation, uncoupled label was removed us-
ing MinElute PCR columns with the exception that prior to elution, cDNA was washed 
once with 35% guanidine hydrochloride to enhance removal of unincorporated dye.  
Analysis of each labeling reaction was performed using a NanoDrop (Thermo Fisher) and 
the following absorbance calculations: 
 
 pmol nucleotides = [OD260 x volume (µl) x (37 ng/µl) x (1000 pg/ng)] 
     (324.5 pg/pmol) 
  
 pmol Cy3 = OD550 x volume (µl) 
      0.15 
 
 pmol Cy5 = OD650 x volume (µl) 
      0.25 
 
 #nucleotides/dye incorporated = pmol cDNA 
              pmol cy dye 
 
 
Microarray design.  H. pylori 26695-specific aminosilane-coated microarrays 
were provided by the Pathogen Functional Genomics Resource Center at the Institute for 
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Genomic Research (Rockville, MD).  Microarray slides contained 13,872 elements, in-
cluding oligonucleotide controls (500 Arabidopsis thaliana 70-mers).  Oligonucleotide 
design was based on 2,572 unique open reading frames (ORFs) (four replicates of each) 
with sequences derived from H. pylori strains 26695 and J99. 
Hybridization and scanning of microarrays.  Aminosilane-coated microarray 
slides were prehybridized in Coplin jars containing 5X SSC (Sigma), 0.1% sodium do-
decyl sulfate (SDS) (Ambion), 1% bovine serum albumin (BSA) (Sigma) and nuclease-
free H2O at 42 °C for 1.5 h.  Following prehybridization, slides were washed four times 
in millipure dH2O, dipped 5-6 times in molecular grade isopropanol (Sigma), spun at 
maximum speed in a microfuge slide centrifuge (VWR) until dry, and cleaned with fil-
tered (0.22 µm) compressed air immediately before use.  For each slide hybridized, equal 
volumes of the appropriate Cy3- and Cy5-labeled probes were combined (yielding 75-
100 pmol of each target), dried under vacuum at 42 °C (Savant), and resuspended in 60 
µl of hybridization buffer containing 40% formamide, 5X SSC, 0.1% SDS, and 0.6 µg/ml 
sheared salmon sperm DNA.  Resuspended probes were denatured by heating to 95 °C 
for 10 min immediately prior to hybridization.  LifterSlip coverslips (25 x 60 mm) (Erie 
Scientific, Portsmouth, NH) were placed over arrays and probe mixtures were added.  
Slides were hybridized for 18 h at 42 °C in hybridization chambers (Argos Technologies, 
Elgin, IL).  A total of 11 hybridizations were performed including 3 biological replicates 
from MGSE-treated cells and 8 biological replicates from quercetin- and resveratrol-
treated cells, respectively. Following hybridization, slides were removed, placed in glass 
staining dishes (Wheaton) and washed sequentially, with shaking (100 rpm) in 1X SSC-
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0.2% SDS (53 °C, 10 min), 0.1X SSC-0.2% SDS (room temperature, 10 min), and 0.1X 
SSC (room temperature, 10 min), dried by centrifugation, and scanned with an Agilent 
G2505B microarray scanner (Santa Clara, CA) . 
Microarray normalization and data analysis.  Microarray data were normalized 
as described by Schmid et al. (2005).  Briefly, scanned TIFF images were processed with 
TIGR Spotfinder software (http://www.tigr.org/software/tm4).  Raw intensity values of 
processed data were normalized by LocFit (LOWESS) normalization in block mode us-
ing TIGR MIDAS software (http://www.tigr.org/software/tm4).  Signal intensities of < 
7,500 were removed prior to analysis to avoid false signal intensity measurements.  Each 
microarray slide contained four in-slide replicates of each oligonucleotide.  Median signal 
intensities of each set of in-slide replicates and experimental replicates were used to cal-
culate log2 and x-fold changes in gene expression. 
Statistics and bioinformatics for identification of differentially expressed 
genes.  The fold change for gene expression was calculated as the average ratio of copy 
number of the genes from treatment samples divided by that from control samples.  The 
fold changes were then transformed into logarithmic scale.  To select the genes that were 
differentially expressed, the concept of false discovery rate (FDR) was utilized (Efron 
and Tibshirani, 2002; Storey and Tibshirani, 2003).  The purpose of FDR is to control for 
the expected fraction of false rejection among the total number of rejections.  FDR main-
tains a balance between the number of false positives and true positives (Storey and Tib-
shirani, 2003) and is equivalent to the family-wise error but with a gain in power (Ben-
gamini and Hochberg, 1995). The strength of the FDR lies on its ‗adaptive‘ nature, i.e. 
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the cut-off P value is selected based on the available information in the data (Cui and 
Churchill, 2003; Sabatti et al., 2003). The significant DNA genes were selected by a pop-
ular method, Significance Analysis of Microarrays (SAM) (Tusher et al., 2001).  SAM 
implements a modified t-test by assigning a score to each marker on the basis of change 
and utilizes permutations to estimate the percentage of markers identified by chance 
(FDR) (Tusher et al., 2001).  The threshold for the false discovery rate was set at 0.10, 
i.e. an estimated 10% of the genes called significant could be false.  Such algorithms ena-
ble the identification of differentially regulated genes even if the fold change is low.  
Primer design for quantitative reverse transcription-PCR (qRT-PCR).  Oli-
gonucleotide primer pairs were designed using OligoPerfect Designer software (Invitro-
gen, Carlsbad, CA) and the H. pylori 26695 genome sequence (Tomb et al., 1997).  All 
primer pairs had 100% template homology, calculated melting temperatures of 59.8 to 
60.5 °C, and amplified products ranging from 81 to 174 bp.  Prior to RT-PCR, each pri-
mer pair was first used to amplify genomic DNA from H. pylori 26695 to confirm target 
amplification and amplicon size; determined by agarose gel electrophoresis. 
qRT-PCR validation of microarray data.  qRT-PCR was performed using the 
gene-specific primer pairs (Table 4.1) of four ORFs determined to be differentially ex-
pressed from microarray experiments.  cDNA was synthesized as previously described 
using 1 µg of total RNA.  No contaminating DNA was detected by PCR.  Amplification 
of cDNA was performed, in triplicate, for 40 cycles at 94 °C, 52 °C, and 72 °C for 30 sec 
each with an iCycler (Bio-Rad).  Accumulation of PCR product was detected during each 
cycle by excitation of SYBR green (Bio-Rad, Hercules, CA) at 490 nm followed by run-
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ning melt curves to reveal non-specific amplification.  Relative fluorescence was deter-
mined by a cycle threshold (Ct) value, defined as the crossover point of the kinetic curve 
with an arbitrary fluorescence level set at 150 relative fluorescence units.  Expression of 
16S rRNA was monitored for sample normalization. 
PCR amplification efficiency.  Because even primer pairs with 100% homology 
to their template can amplify with significantly different efficiencies (Pfaffl, 2001), pri-
mer pairs were first evaluated using H. pylori 26695 DNA.  The efficiency of each primer 
pair was determined using the slopes calculated from standard curves prepared from cor-
responding Ct values determined using 10-fold serial dilutions of starting DNA, and de-
fined as: 
primer amplification efficiency (E) = 10 
(-1/slope) 
 
 
Calculation of gene expression.  Using Ct values of both control and treated 
samples and the formulas below (Pfaffl, 2001), gene expression was determined, cor-
rected for the internal 16S rRNA standard, and reported as fold change relative to no 
treatment controls. 
 
 gene fold change = (E) 
avg. Ct control – avg. Ct treated 
 
 absolute gene expression = (E target) 
ΔCt target
 
                  (E 16S rRNA) 
ΔCt 16S rRNA
 
 
 
Results 
Significant changes in H. pylori gene expression after 15 min exposure to 
MGSE, quercetin, and resveratrol.  Microarray analysis was used to determine the pat-
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terns of relative transcript amounts in cells exposed to sub-inhibitory concentrations of 
quercetin, resveratrol, and MGSE in an attempt to determine/highlight their possible me-
chanism(s) of action against H. pylori 26695. 
 The amount of compound used in each experiment was determined previously by 
microbroth and agar dilution assays and represented concentrations two-fold lower than 
the average minimal inhibitory concentration recorded.  In this study the concentrations 
of quercetin, resveratrol, and MGSE were 32 µg/ml, 16 µg/ml, and 0.1 mg total phenol-
ics/ml, respectively.  Total RNA was extracted from each culture 15 min after addition of 
each compound/extract or DMSO (control).  This short time period was chosen to minim-
ize possible secondary and downstream/bystander effects that might arise during pro-
longed treatment; thus interfering with analysis and interpretation of results.  Hybridiza-
tion intensity for each gene on the array was compared for the compound/extract-treated 
and DMSO control samples (Tables 4.2-4.4). 
Of the total number of ORFs subjected to data analysis from each treatment, few 
transcripts were significantly altered with 63, 39, and 29 genes differentially expressed 
upon 15 min exposure to MGS extract, quercetin or resveratrol, respectively.  Of the 
genes showing altered transcript amounts in response to each treatment, ~30% encoded 
hypothetical proteins without known functions, 22% encoded proteins involved in tran-
scription/translation, 15% encoded proteins involved in energy production/metabolism, 
whereas genes related to other cellular processes, amino acid biosynthesis, etc. accounted 
for the remainder, ~34% (Figure 4.1). 
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Of the genes involved in transcription/translation, 20 code for ribosomal proteins 
(3 induced, 17 repressed).  Interestingly, histone-like DNA binding protein (hup) 
(HP0835), shikimate 5-dehydrogenase (aroE) (HP1249), and ATP synthase F1 subunit A 
(atpA) (HP0828) were induced upon exposure to quercetin.  In resveratrol-treated cells, 
translation initiation factor 2 (infB) (HP1048) was induced.  In addition, cagA and ureA 
were repressed in MGSE-treated cells whereas cagA, ureE and I, were repressed follow-
ing quercetin and resveratrol treatment, respectively. 
Validation of microarray results.  To validate the ability of H. pylori microar-
rays to determine significant changes in gene expression, quantitative reverse transcrip-
tase polymerase chain reaction (qRT-PCR) was performed.  Four representative genes 
from those found to change significantly following treatment were chosen for further 
analysis.  To optimize PCR analysis, the efficiency of each primer pair was determined 
prior to testing and ranged from 87.7 to 94.0 %.  As shown in Figure 4.2, transcript levels 
of cagA and ureA were repressed following MGSE treatment while  atpC and hup were 
induced following MGS and quercetin treatment, respectively.  Thus, qRT-PCR confirms 
the ability of microarray to detect changes in selected gene expression. 
Discussion 
 DNA microarrays have been increasingly used to measure changes in gene ex-
pression levels.  For example, antibiotic-induced gene expression has previously been 
studied using microarray hybridization (Wilson et al., 1999; Gmuender et al., 2001).  
However, unlike these studies reporting the effects of low concentration antibiotic expo-
sure on Mycobacterium tuberculosis and Haemophilus influenzae transcript patterns, 
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quercetin and resveratrol‘s primary target(s) against H. pylori are unknown.  In those stu-
dies, only 14 and 5 genes were differentially expressed, respectively, with a majority di-
rectly associated with each drug‘s reported mode of action.  Therefore, using a similar 
approach, we chose to treat H. pylori 26695 with sub-inhibitory concentrations of each 
compound for a short time period with the goal of revealing each compound‘s likely pri-
mary target(s).  Although fewer genes were differentially expressed given these condi-
tions, we believe that by using this strategy, the most interpretable results were obtained 
and likely represent the compounds‘ primary mechanism(s) of action.  Alternatively, use 
of high inhibitor concentrations for extended periods of time changes the expression of a 
large set of genes; however, these effects may be secondary to the action of the drug 
(Palzkill, 2001).  In addition to highlighting suspected primary targets, determination of 
the function of unknown genes induced in the primary response to antibiotic exposure 
may uncover potential new targets for future antimicrobial development. 
The data presented here indicate that H. pylori responds to resveratrol and querce-
tin quite differently with only one overlapping gene (outer membrane protein, omp30) 
(HP1395) detected for the two treatments.  This was not surprising given these com-
pounds belong to different chemical classes; quercetin being a flavonoid and resveratrol a 
stilbene, with highly different structures (Pastrana-Bonilla et al., 2003).  This trend of 
non-overlapping gene expression has also been reported when examining transcription 
patterns between other antimicrobials with different modes of action such as triclosan (a 
possible fatty acid biosynthesis inhibitor) and tetracycline (translation inhibitor) in Strep-
tococcus pneumoniae (Ng et al., 2003).  Furthermore, antibiotics acting on the same bac-
119 
 
terial target but by different mechanisms have also been reported to result in different 
gene expression profiles (Gmeunder et al., 2001).  In addition, we have previously shown 
that resveratrol and quercetin act synergistically against H. pylori in vitro further support-
ing their different mode(s) of action. 
Following array analysis, some commonality in expression of selected genes was 
found between MGSE and quercetin albeit at different levels (most likely due to concen-
tration differences and additional unknown factors).  Because MGSE was previously de-
termined to contain relatively high levels of both quercetin and resveratrol by HPLC; 
which were found to be the most active major phenolics following susceptibility testing 
(Chapter 3), we hypothesized that expression patterns of selected genes may be similar 
between purified and crude preparations.  However, due to the overall complexity of the 
MGSE (i.e. the numerous additional unknown components undoubtedly present), natural 
synergism, and inability to standardize quercetin and resveratrol levels, this was not 
achievable.  However, some degree of overlap in expression was observed and rather 
surprising.  Of the similar changes detected, the most interesting were secondary effects 
involving genes encoding for known H. pylori virulence factors (i.e. CagA and urease) 
and are discussed later.   
Muscadine grape skin extract. Of the genes significantly altered following 
MGSE exposure, the majority are diverse in function and not clearly indicative of any 
individual target; likely reflecting the complex synergistic antimicrobial action found na-
turally in MGSE.  However, some are in support of H. pylori cell membrane protein inhi-
bition/damage previously hypothesized for this extract including ATP synthase F1 sub-
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unit C, cytochrome c oxidase, and cytochrome c551 peroxidase (all induced).  In addi-
tion, the clpA gene, coding for the ATP-dependent caseinolytic protease (Clp), was also 
induced upon MGSE exposure.  Interestingly, these proteins are important in resistance 
against environmental stress, antibiotic treatment, and host immune defenses for a num-
ber of bacteria (Loughlin et al., 2009).  While ClpP is the proteolytic subunit, ClpA acts 
as both a chaperone and an ATPase driving the degradation of damaged or mismade pro-
teins.  Because polyphenols are suspected to cause protein damage in H. pylori, induced 
expression of clpA may implicate the organism‘s attempt to degrade/remove damaged 
protein. 
H. pylori gene yihK (HP0480) coding for protein elongation factor (EF-G) (homo-
log) and pheT (HP0402), aminoacyl-tRNA synthetase, were also induced; suggesting 
possible targeting of these proteins resulting in reduced protein synthesis.  In line with 
this, 10 transcripts for ribosomal proteins were repressed (Table 1).  Ribosomal proteins, 
known for their essential role in translation, also act as sensors in response to environ-
mental stimuli such as temperature change and antibiotic treatment with corresponding 
expression of heat shock genes (VanBogelen and Neidhardt, 1990; Jones et al., 1992).  
Following treatment, a definite heat shock response was observed; however, these genes 
(groEL, dnaK, and grpE) (HP0010, HP0109, HP0110) were also repressed and may only 
be explained by the corresponding reduction in ribosomal protein. 
H. pylori cell binding factor-2, a secretory protein, was repressed following treat-
ment and contributes to activation of epidermal growth factor receptor and activation of 
vascular endothelial growth factor, important in H. pylori pathogenesis (Basu et al., 
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2008).  Serine protease was also repressed.  Although primarily known for its role in pro-
tein quality control, it was recently identified as a new secreted virulence factor as it 
cleaves the ectodomain of the cell-adhesion protein E-cadherin; disrupting epithelial bar-
rier functions which allow H. pylori to access the intercellular space (Hoy et al., 2010).  
Catalase was also repressed following treatment.  Despite being nonessential for in vitro 
viability, this enzyme is of key importance in H. pylori‘s antioxidant defense mechanisms 
upon colonization and may support earlier in vivo findings (Harris et al., 2002). 
Although difficult to interpret given the complex nature of MGSE treatment, these 
results may partially support our earlier findings on the anti-H. pylori properties of 
MGSE (Brown et al., 2009) while further emphasizing the need to determine the most 
active compound(s) in plant-based extracts prior to gene expression studies. 
Resveratrol. Following treatment with resveratrol, a transcript profile similar to 
that of the bacterial stringent response was observed (Durfee et al., 2008).  Of the tran-
scripts significantly altered following treatment, translation initiation factor 2 (infB) was 
induced whereas GTP-dependent nucleic acid-binding protein was repressed.  In addition, 
respiration-related gene expression was affected with NADH dehydrogenase enzymes 
and cytochrome c oxidoreductase levels significantly reduced.  Not only are these 
changes in line with the stringent response process but have also been observed in other 
microorganisms following treatment with translation inhibitors (Ng et al., 2003).  In addi-
tion, neither quercetin nor MGS-treated cells exhibited this response even though samples 
were prepared under identical conditions.  Therefore, these results may suggest that res-
veratrol‘s primary mode of action against H. pylori is related to translation inhibition. 
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Translational IF-2 is highly conserved among prokaryotes and essential for the 
GTP-dependent binding of fMet-tRNA to ribosomes to form the 70S initiation complex 
(Kyrpides and Woese, 1997; Gualezi and Pon, 1990).  IF-2 catalyzes the ribosome-
dependent hydrolysis of GTP to GDP and inorganic phosphate (Pi) concomitant with the 
formation of the 70S initiation complex.  It also catalyzes the uncoupled ribosome-
dependent hydrolysis of GTP in the absence of other components required for imitation.  
Molecules like thiostrepton (Brandi et al., 2004), some structural analogs of fMet-
adenosine/NacPhe-adenosine (Delle Fratte et al., 2002), and guanosine-3′-5′-bis (diphos-
phate) (ppGpp) (Milon et al., 2006), capable of inhibiting IF-2 activity, have been found.  
However, no antibiotic selectively targeting its functions has been reported to date.  Thus, 
IF-2 may be regarded as an ideal target for new bacteria-specific drugs for which no re-
sistance mechanisms have yet been developed (Letizia Brandi et al., 2007). 
A number of antibiotics that inhibit bacterial protein synthesis are thought to act 
by stabilizing particular conformations of the ribosome; preventing structural changes 
that occur during translation.  Thiostrepton and micrococcin are two examples which 
bind to the L11-bindng region of the 23S rRNA (the GTPase center of the ribosome).  
These molecules are believed to interfere with the function of the factors that interact 
with this region by stabilizing the L11-binding region so that it is unable to undergo a ne-
cessary conformational change (Cameron et al., 2002) 
Given the possibility of IF-2 inhibition, induction of infB would be expected, sup-
porting our hypothesis.  However, although strongly indicative of translation inhibition, 
further studies are necessary to confirm resveratrol‘s effect on IF-2.  Tests to determine 
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resveratrol‘s interaction with some of the main activities of this factor, such as 1) recog-
nition and binding of the initiator tRNA; 2) codon-dependent ribosomal binding of fMet-
tRNA leading to the formation of a 30S or 70S initiation complex; 3) ribosome dependent 
hydrolysis of GTP; and 4) accommodation of fMet-tRNA in the ribosomal P-site and 
formation of the first peptide bond (initiation dipeptide formation) may be useful in de-
termining resveratrol‘s precise activity against H. pylori. 
Quercetin. Of the transcripts significantly altered following quercetin treatment, 
three were selected for further discussion; shikimate 5-dehydrogenase (aroE), histone-
like DNA binding protein (HU) (hup) and F0F1 ATP synthase subunit A (atpA), as these 
may play key roles in H. pylori‘s response to quercetin and/or this compound‘s primary 
anti-H. pylori activity. 
Previous studies have shown that the shikimate pathway is essential for the syn-
thesis of key metabolites such as folic acid, aromatic amino acids, and ubiquinone in bac-
teria (Parish and Stoker, 2002).  Recently, enzymes involved in this pathway; including 
shikimate dehydrogenase (SDH), the fourth enzyme in the pathway responsible for cata-
lyzing the NADPH-dependent reduction of 3-dehydroshikimate to shikimate, have re-
ceived increased attention in the development of nontoxic antimicrobial agents (Coggins 
et al., 2003).  In support of this, Han et al. (2006) reported curcumin (diferuloylmethane), 
regarded as the most active constituent of Curcuma longa (i.e. turmeric), to be a non-
competitive inhibitor of SDH.  More specifically, the antimicrobial action of curcumin 
against multiple H. pylori isolates in vitro and during infections in mice was recently re-
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ported; further supporting the potential use of polyphenols against H. pylori infection (De 
et al., 2009). 
In this study, we found that quercetin caused an increase in aroE transcripts.  We 
hypothesize that this may have been due to quercetin binding to SDH allosteric sites, 
much like curcumin, thereby reducing SDH activity and inducing aroE expression in or-
der to compensate for this loss.  This result may suggest that different natural compounds 
may share antimicrobial targets.  However, quercetin‘s interaction with SDH and aroE 
should be explored further. 
In addition to aroE, hup was also induced upon exposure to quercetin.  The hup 
gene codes for HU which is important in bacterial genome compaction (i.e. introduction 
of negative DNA supercoiling) and possibly specific regulatory functions in H. pylori 
(Chen et al., 2004).  Supercoiling and topoisomerases influence a variety of DNA activi-
ties such as transcription, transposition, recombination and DNA replication (Matthews, 
1992).  DNA gyrase, like HU, introduces and maintains negative supercoils, also contri-
buting to DNA compaction. (Drlica and Snyder, 1978).  Because HU stimulates DNA 
gyrase and lowers the activity of topoisomerase I, this facilitates the maintenance of 
intracellular supercoiling; yet the specific HU-gyrase interactions are not currently clear; 
especially in H. pylori (Malik et al., 1996). 
Quercetin was previously found to inhibit DNA gyrase and introduce DNA clea-
vage in E. coli via its interaction with DNA or gyrase‘s ATP binding site on the 24 kDa 
fragment of gyrase B, inhibiting gyrase B ATPase activity (Plaper et al., 2003).  The later 
mechanism is similar to novobiocin (a coumarin) which inactivates the enzyme without 
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introducing DNA strand breaks (Gmuender et al., 2001).  Later, green tea catechins were 
also found to inhibit gyrase activity by the same mechanism (Gradišar et al., 2007).  
Therefore, we expected to see changes in H. pylori gene expression consistent with these 
findings.   However, analysis of array data did not reveal DNA gyrase (induction) or to-
poisomerase (repression) gene products, possibly due to poor labeling or hybridization.  
Although we may have missed expression level changes in DNA gyrase and topoisome-
rase I, hup was clearly induced.  Therefore, given HU‘s close association with DNA gy-
rase, one may argue that if H. pylori DNA gyrase is in fact inhibited by quercetin, an in-
crease in HU (and DNA gyrase for that matter) may be the cell‘s attempt to maintain an 
optimal supercoiling degree to compensate for this deficiency.  Additional work may be 
necessary to further verify these results; however, our data appear to be in agreement 
with other studies, supporting quercetin‘s possible mode of action against H. pylori. 
Recently, the inhibition of ATPase activity of E. coli ATP synthase by polyphe-
nols was reported (Dadi et al., 2009).  In that study, quercetin inhibited ATPase activity 
ca. 80% at low concentration (IC50 = 33µM) with maximal inhibition achieved within 15 
min, and was reversible upon removal of inhibitor.  Interestingly, our results showed an 
increase in atpA expression following quercetin treatment.  Furthermore, previous phase-
contrast microscopy experiments showed reduced H. pylori motility in the presence of 
quercetin indicating a possible reduction in proton-motive force—further supporting 
quercetin‘s interaction with this enzyme in H. pylori. 
 In addition to the three genes discussed above, 36 other genes also showed a 
changed expression rate.  Whether these are primary or secondary effects of quercetin 
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remains to be determined.  However, it is unlikely that these differences are artifacts de-
rived from culture conditions as all cells were grown under identical conditions and may 
be important in understanding quercetin‘s full anti-H. pylori activity.  Finally, hypotheti-
cal proteins differentially expressed following quercetin treatment are noteworthy and 
may be subject for future detailed functional genomic studies. 
H. pylori virulence factors. In this study, both quercetin and MGSE-treated cells 
showed reduced cagA levels.  CagA is known to elicit a strong immunological response 
and implicated in H. pylori pathogenesis through its interruption of host cell signal trans-
duction, actin cytoskeleton rearrangement, and interleukin-8 production—promoting in-
flammation and subsequent host cell damage (Sharma et al., 1995; Censini et al., 1996; 
Prinz et al., 2003).  We have previously reported that MGSE is effective at reducing host 
cell damage/death in a gastric epithelial cell line (ATCC CRL-1739) which may be par-
tially due to inhibition of CagA toxin production (Brown et al., 2009).  We have also 
shown using H. pylori-infected mice, that both MGS powder (5-10%) and quercetin sig-
nificantly reduced gastric inflammation and host cell damage following prolonged treat-
ment, even while H. pylori levels remained relatively unchanged; also suggesting the 
possibility of CagA inhibition. 
In addition to cagA, genes associated with H. pylori urease were also repressed 
following treatment with MGSE.  However, unlike cagA, no changes were detected in 
quercetin-treated cells but were detected following resveratrol treatment.  Genes differen-
tially expressed were non-overlapping; representing two operons (ureAB and ureIEFGH), 
which was surprising given that resveratrol was also detected in MGSE.  However, dif-
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ferences in resveratrol concentration and/or additional unknown factors may have contri-
buted to this result. 
In MGSE-treated cells, urease subunit A (ureA) (HP0073) was significantly re-
pressed.  UreA is one of two structural subunits (ureAB) forming the urease enzyme with 
a predicted molecular mass of 26.5 kDa (Mobley, 2001).  Urease is a Ni
2+
-containing cy-
toplasmic enzyme that converts urea into bicarbonate and ammonia.  H. pylori urease is 
essential for colonization of the stomach as it allows survival under acidic conditions—
accounting for up to 15% of the total protein synthesized by the organism (Prinz et al., 
2003; Mobley et al., 1995).  These products generate a protective alkaline microenviron-
ment (optimal pH of 7.0) and allow the organism to persist in the gastric environment 
(Mobley, 2001).  Interestingly, other studies evaluating the anti-H. pylori activities of 
various plant-based extracts have also reported urease inhibition (Lin et al., 2001; Xiao et 
al.., 2007) further supporting results from this study.   
In resveratrol-treated cells, ureI (HP0071) and ureE (HP0070) transcripts were 
significantly repressed but ureA and B were not.  The ureI gene, unique to H. pylori, en-
codes for an integral cytoplasmic protein involved in the formation of an H
+
-gated, urea-
specific pore; allowing entry of urea at low pH (Ang et al., 2001).  Previous studies have 
concluded that urease-dependent adaptation to acidity in vitro depends on the transport 
function of UreI (Mobley et al., 2001).  Furthermore, deletion mutants are unable to co-
lonize mice, supporting the role of UreI in gastric acid adaptation and survival in vivo 
(Sachs et al., 2001; Skouloubris et al., 1998).  The ureE gene, also repressed following 
resveratrol treatment and closely associated with ureI contributes (alongside remaining 
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accessory genes ureF, ureG, and ureH) to production of the active product for nickel in-
corporation into the enzyme‘s active site during the final step of urease biosynthesis.  
Like ureI, for synthesis of a catalytically active urease enzyme, ureE (in addition to ac-
cessory genes) must also be expressed (Mobley et al., 2001).   
Although vacA was detected during microarray analysis, its expression was not 
repressed at a significant level following any treatment and was therefore not reported.  
However, other studies have shown the anti-VacA activities of polyphenols; especially 
those from red wine, green tea, and even apple peel (Ruggiero et al., 2006; Tombolo et 
al., 2003, Pastene et al., 2010).  Although vacA expression levels were not changed, this 
does not negate the role of currently unknown polyphenolic constituents against VacA 
toxin.  Based on previous studies reporting VacA inhibition by polyphenols, MGSE may 
also neutralize VacA by 1) direct VacA-polyphenol interaction precluding the insertion 
of VacA into the eukaryotic membrane or 2) interference with vacuolization or channel 
formation caused by VacA toxin.  However, this has yet to be fully studied with MGSE 
but does support our earlier findings showing reduced gastric epithelial cell damage (pri-
marily caused by VacA) following MGSE treatment (Brown et al., 2009).  In addition, 
anti-adhesive properties of polyphenols (including those in MGSE) have also been pro-
posed (Burger et al., 2002) but were not revealed in this study. 
Collectively, quercetin, resveratrol, and MGSE repressed cagA, ureA, ureE, ureI, 
and vacA (not significant) expression.  Although the exact regulatory mechanism behind 
these changes were not elucidated, our results do support that phenolic compounds may 
be effective at reducing H. pylori virulence via repression of these genes; however, addi-
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tional studies are necessary to fully understand these interactions.  Furthermore, the pre-
cise antibacterial mechanism(s) of quercetin and resveratrol were not confirmed in this 
study, but results are in line with previous findings obtained in our laboratory and other 
groups on these compounds and support future, more specific studies into the exact me-
chanism(s) by which these compounds exert their anti-H. pylori activity. 
In conclusion, this study shows that microarrays may be useful tools in the cha-
racterization of novel plant-based antimicrobials.  This is the first report describing H. 
pylori gene expression change upon treatment with any natural compound.  Results also 
support previous findings on the anti-H. pylori activity of polyphenols quercetin and res-
veratrol.  Additionally, this study demonstrates that with low inhibitor concentration and 
short exposure, only a few genes show a clear change in expression and may be optimal 
for the analysis of primary response mechanisms.  However, these may be concentration- 
and/or time-dependent and require additional preliminary work to optimize conditions, 
but may be useful in eliminating many secondary effects commonly seen in array studies.  
It is also our opinion that using crude extracts may not be  suitable in the screening 
process for specific antimicrobial targets of polyphenolic compounds as results are com-
plicated given numerous uncontrollable factors. 
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Figure Legend 
 
FIGURE 4.1. Distribution of functions of selected genes whose relative transcript 
amounts were affected by treatment with MGS, quercetin, or resveratrol.  The relative 
abundance is expressed as a percentage of the total number of genes whose relative tran-
script amount was affected by each treatment (Tables 2-4) and includes both increased 
and decreased transcript amounts. 
 
FIGURE 4.2. Changes in transcript levels upon exposure of H. pylori 26695 to MGS ex-
tract (cagA, ureA, atpC) and quercetin (hup) determined by qRT-PCR.  The mean log2 
expression and standard deviation is reported for three independent replicates.  The 16S 
rRNA gene was used for normalization. 
 
 
 
 
 
 
 
 
 
 
 
 
136 
 
TABLE 4.1. H. pylori genes and primer pairs selected for real-time RT-PCR. 
 
Gene HP no.a Forward primer Reverse primer 
ureA HP0073 CCTTCTTGCATCAATTCAGCCGCA AGCGGTAGCTTTGATTAGTGCCCA 
hup HP0835 GCGATCAGTGCCTTTACTTTGGCA TCGCTTCCTGGCACTTTACCTTCT 
F0F1  HP1212 ATCACTTGCGCTTCAATCATCGCC ATTACAGGCACAGCGAGAAACCCA 
cag26 HP0547 TGTTGAGGGAGTCGCTGACATTGA GTGGCGTTCCAATCGTGTTTGTCT 
16S rRNA  ATGGATGCTAGTTGTTGGAGGGCT TTAAACCACATGCTCCACCGCTTG 
 
a
 H. pylori gene designation (Tomb et al., 1997) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
TABLE 4.2. Differentially expressed genes of H. pylori 26695 upon exposure to MGS 
extract. 
 
Gene set Category and TIGR no. Symbol Putative function n-fold 
     
Induced genes Protein degradation    
 HP0033 clpA Chaperone and ATPase 1.2 
 HP0363 pcm 
Protein-L-isoaspartate O-
methyltransferase 
1.8 
     
 Unknown function    
 HP0412  Hypothetical protein 1.2 
 HP0563  Hypothetical protein 1.6 
 HP0571  Hypothetical protein 1.6 
 HP0637  Hypothetical protein 2.1 
 HP0813  Hypothetical protein 1.0 
 HP1083  Hypothetical protein 1.5 
 HP1175  Hypothetical protein 1.3 
 HP1217  Hypothetical protein 1.5 
     
 Motility    
 HP1377 fliW Flagellar assembly protein 1.1 
     
 Transcription/translation    
 HP0480 yihK GTP-binding protein, fusA homolog 1.1 
     
 Energy metabolism    
 HP1212 atpC ATP synthase F1, subunit C 1.6 
 HP0147 fixP Cytochrome c oxidase 1.1 
 HP1461  Cytochrome c551 peroxidase 2.1 
     
 Cell envelope    
 HP1395 omp30 outer membrane protein 1.2 
     
 Amino acid biosynthesis    
 HP1210 cysE serine acetyltransferase 1.5 
     
 
Fatty acid and phospholipid 
metabolism 
  
 
 HP1052 lpxC N-acetylglucosamine deacetylase 1.1 
 HP0215 cdsA CDP-diglyceride synthetase 1.3 
     
 Protein biosynthesis    
 HP0402 pheT Aminoacyl-tRNA synthetase, ligase 2.0 
     
 Biosynthesis of cofactors    
 HP0306  Porphyrin biosynthetic protein 1.0 
 HP0625  Isoprene biosynthetic protein 2.1 
 HP0020 nspC Norspermidine biosynthetic protein 1.2 
     
 Purine biosynthesis    
 HP1218 purD Glycinamide ribonucleotide synthetase 1.3 
 HP1193 akR Aldo-keto reductase, putative 1.0 
     
Repressed genes Transcription/translation    
 HP1196 rps7 Ribosomal protein S7, 30S -1.1 
 HP1197 rpsL Ribosomal protein S12, 30S -1.4 
 HP1200 rplJ Ribosomal protein L10, 50S -1.0 
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 HP1244 rpsR Ribosomal protein S18, 30S -1.1 
 HP1245 ssb Single-stranded DNA binding protein -1.2 
 HP1303 rplR Ribosomal protein L18, 50S -1.5 
 HP1305 rpsH Ribosomal protein S8, 30S -1.3 
 HP1306 rpsN Ribosomal protein S14, 30S -0.9 
 HP1308 rplX Ribosomal protein L24, 50S -1.1 
 HP1309 rplN Ribosomal protein L14, 50S -1.2 
 HP1311 rpmC Ribosomal protein L29, 50S -1.5 
 HP1312 rplP Ribosomal protein L16, 50S -1.4 
 HP1019 htrA Serine protease -1.2 
 HP0569 engD 
GTP-dependent nucleic acid-binding pro-
tein, putative translation- associated 
GTPase 
-0.9 
     
 Cellular processes    
 HP0547 cagA Cytotoxin-associated gene A -1.5 
 HP0010 groEL Chaperone and heat shock protein -1.0 
 HP0109 dnaK Chaperone and heat shock protein, 70 kDa -1.1 
 HP0110 grpE 
Cochaperone and heat shock protein, 24 
kDa 
-1.3 
 HP0175  Cell binding factor 2 -1.8 
     
 
Central intermediary meta-
bolism 
  
 
 HP0073 ureA Urease alpha subunit  -2.3 
 HP0875  Catalase -1.0 
     
 Cell envelope    
 HP0317 hopU Outer membrane protein -0.9 
 HP1243 omp28 Outer membrane protein -0.6 
     
 Unknown function    
 HP0102  Hypothetical protein -1.0 
 HP0185  Hypothetical protein -1.9 
 HP0367  Hypothetical protein -1.0 
 HP0659  Hypothetical protein -1.0 
 HP0697  Hypothetical protein -1.3 
 HP0719  Hypothetical protein -0.7 
 HP0720  Hypothetical protein -1.5 
 HP0721  Hypothetical protein -1.5 
 HP0731  Hypothetical protein -2.1 
 HP0733  Hypothetical protein -1.3 
 HP1124  Hypothetical protein -1.8 
     
 Energy metabolism    
 HP0695 hyuA Hydantoin utilization protein A -1.3 
 HP0027 Icd Isocitrate dehydrogenase -1.1 
 HP0690 fadA 
Acetyl coenzyme A acetyltransferase 
(thiolase) 
-1.1 
     
 Transport and binding     
 HP1172 glnH 
Glutamine ABC transporter, periplasmic 
glutamine-binding protein  
-1.3 
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TABLE 4.3. Differentially expressed genes of H. pylori 26695 upon exposure to querce-
tin. 
 
Gene set Category and TIGR no. Symbol Putative function n-fold 
     
Induced genes Transcription/translation    
 HP0835 hup Histone-like DNA-binding protein 0.5 
 HP1302 rpsE Ribosomal protein S5, 30S 0.5 
 HP1447 rpmH Ribosomal protein L34, 50S 0.6 
     
 Unknown function    
 HP0031  Hypothetical protein 0.4 
 HP0129  Hypothetical protein 0.6 
 HP0149  Hypothetical protein 0.4 
 HP0199  Hypothetical protein 0.4 
 HP0565  Hypothetical protein 0.4 
 HP0641  Hypothetical protein 0.4 
 HP0891  Hypothetical protein 0.6 
 HP0920  Hypothetical protein 0.4 
 HP0947  Hypothetical protein 0.7 
 HP1289  Hypothetical protein 0.5 
     
 
Fatty acid and phospholipid 
metabolism 
  
 
 HP0559 acpP Acyl carrier protein 0.3 
 HP1375 lpxA UDP-N-acetylglucosamine acyltransferase 0.5 
     
 Cell envelope    
 HP1395 omp30 Outer membrane protein 0.6 
 HP1512 frpB Iron-regulated outer membrane protein 0.5 
     
 Motility    
 HP1240 maf Motility accessory factor-like protein 0.4 
     
 Energy metabolism    
 HP0824 trxA Thioredoxin reductase 0.4 
 HP1458  Thioredoxin, putative 0.6 
 HP0857  Phosphoheptose isomerase 0.4 
 HP1100  Phosphogluconate dehydratase 0.3 
 HP1249 aroE Shikimate 5-dehydrogenase 0.7 
 HP0828 atpA ATP synthase F1, subunit A 0.5 
 HP0145  
Cbb3-type cytochrome c oxidase subunit 
II 
0.5 
 HP0510  Dihydrodipicolinate reductase 0.5 
     
 Cellular processes    
 HP0542 cag21 cag pathogenicity island protein  0.5 
     
Repressed genes Transcription/translation    
 HP1200 rplJ Ribosomal protein L10, 50S -0.4 
 HP1308 rplX Ribosomal protein L24, 50S -0.5 
 HP1309 rplN Ribosomal protein L14, 50S -0.8 
 HP1316 rplB Ribosomal protein L2, 50S -0.4 
 HP1293  
DNA-directed RNA polymerase subunit 
alpha 
-0.5 
     
 Unknown function    
 HP0102  Hypothetical protein -0.5 
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 HP0697  Hypothetical protein -0.6 
 
Fatty acid and phospholipid 
metabolism 
  
 
 HP0561 fabG 3-ketoacyl-(acyl-carrier-protein) reductase -0.6 
     
 Energy metabolism    
 HP0695 hyuA Hydantoin utilization protein -1.1 
 HP0696  N-methylhydantoinase -0.5 
     
 Cell envelope    
 HP0743 mreB Rod shape-determining protein 
-0.5 
 
     
 Cellular processes    
 HP0547 cagA Cytotoxin-associated gene A -0.8 
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TABLE 4.4. Differentially expressed genes of H. pylori 26695 upon exposure to resvera-
trol. 
 
Gene set Category and TIGR no. Symbol Putative function n-fold 
     
Induced genes Cellular processes    
 HP0323 nucT DNA transformation 0.6 
 HP0531 cag11 cag pathogenicity island protein 0.5 
     
 Cell envelope    
 HP0896 omp19 Outer membrane protein 0.4 
 HP1395 omp30 Outer membrane protein 0.4 
     
 Transcription/translation    
 HP1048 infB Translation initiation factor IF-2 1.0 
 HP1203 nusG Transcription antitermination protein 0.6 
     
 HP0514 rpll Ribosomal protein L9, 50S 0.8 
     
 Unknown function    
 HP0129  Hypothetical protein 0.4 
 HP0217  Hypothetical protein 0.8 
 HP0222  Hypothetical protein 0.6 
 HP1005  Hypothetical protein 0.9 
 HP1049  Hypothetical protein 0.6 
 HP1074  Hypothetical protein 0.5 
 HP1122  Hypothetical protein 0.5 
 HP1242  Hypothetical protein 0.4 
     
 Amino acid metabolism    
 HP1050 trhB Homoserine kinase 0.7 
     
 Energy metabolism    
 HP1099 eda 
2-keto-3-deoxy-6-phoshogluconate aldo-
lase 
0.6 
     
Repressed genes Transcription/translation    
 HP0569 engD 
GTP-dependent nucleic acid-binding pro-
tein, putative translation- associated 
GTPase 
-0.7 
 HP1310 rpsQ Ribosomal protein S17, 30S -0.5 
 HP1317 rplW Ribosomal protein L23, 50S -0.4 
     
 Unknown function    
 HP0080  Hypothetical protein -0.4 
     
 Transport and binding    
 HP1400 fecA Iron (III) dicitrate transport protein -0.6 
 HP0490  Potassium channel protein, putative -0.6 
     
 Energy metabolism    
 HP1272  NADH dehydrogenase subunit M -0.6 
 HP1273  NADH dehydrogenase subunit N -0.7 
 HP1539 fbcH 
Ubiquinol cytochrome c oxidoreductase, 
cytochrome b subunit 
-0.6 
     
 Cellular processes    
 HP1160  Metolloprotease (putative) -0.6 
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Central intermediary meta-
bolism 
  
 
 HP0070 ureE urease accessory protein -0.6 
 HP0071 ureI urease accessory protein -0.7 
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FIGURE 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
FIGURE 4.2. 
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CHAPTER FIVE 
CONCLUSION 
In this study, we examined the properties of muscadine grape skin and constitu-
tive polyphenolic compounds against Helicobacter pylori.  Both muscadine grape skin 
and quercetin inhibited bacterial growth in vitro and in vivo while significantly reducing 
inflammation and gastric damage in H. pylori-infected mice.  The major phenolics quer-
cetin and resveratrol, located in the skin, have the strongest anti-H. pylori activity in vi-
tro, especially when used in combination, and are independent of pH.  Neither quercetin 
nor resveratrol affected H. pylori outer membrane integrity or significantly altered cell 
surface hydrophobicity; however, muscadine grape skin did suggesting additional un-
known factors not revealed in this study.  In addition, quercetin reduced H. pylori motili-
ty while being transported into the cell cytosol.  Gene expression studies showed that mi-
croarrays may be useful in the characterization of novel plant-based antimicrobials while 
supporting previous findings on the anti-H. pylori potential of polyphenols quercetin and 
resveratrol.  Furthermore, this study demonstrates that with low inhibitor concentration 
and short exposure, only a few genes show a clear change in expression and may be op-
timal for the determination of primary response mechanisms.  However, these may be 
concentration- and/or time-dependent and require additional preliminary work to optim-
ize conditions, but may be useful in eliminating many secondary effects commonly seen 
in array studies.  It is also our opinion that using crude extracts are not suitable in the 
screening process for specific antimicrobial targets of polyphenolic compounds as results 
are complicated given numerous uncontrollable factors. 
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Our results indicate that muscadine grape skin and constitutive polyphenolics 
quercetin and resveratrol exert strong anti-H. pylori activity and may have the potential to 
be incorporated into an effective, diet-based approach for prevention and/or treatment of 
H. pylori infection. 
 
